Alzheimer's disease due to loss of function

A new synthesis of the available data

Kepp, Kasper Planeta

Published in:
Progress in Neurobiology

Link to article, DOI:
[10.1016/j.pneurobio.2016.06.004](https://doi.org/10.1016/j.pneurobio.2016.06.004)

Publication date:
2016

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Kepp, K. P. (2016). Alzheimer's disease due to loss of function: A new synthesis of the available data. *Progress in Neurobiology*, 143, 36-60. <https://doi.org/10.1016/j.pneurobio.2016.06.004>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Alzheimer's disease due to loss of function: A new synthesis of the available data

Kasper P. Kepp*

Technical University of Denmark, DTU Chemistry, DK-2800 Kongens Lyngby, Denmark

*Correspondence: Email: kpj@kemi.dtu.dk

Abstract

Alzheimer's Disease (AD) is a highly complex disease involving a broad range of clinical, cellular, and biochemical manifestations that are currently not understood in combination. This has led to many views of AD, e.g. the amyloid, tau, presenilin, oxidative stress, and metal hypotheses. The amyloid hypothesis has dominated the field with its assumption that buildup of pathogenic β -amyloid ($A\beta$) peptide causes disease. This paradigm has been criticized, yet most data suggest that $A\beta$ plays a key role in the disease. Here, a new loss-of-function hypothesis is synthesized that accounts for the anomalies of the amyloid hypothesis, e.g. the curious pathogenicity of the $A\beta_{42}/A\beta_{40}$ ratio, the loss of $A\beta$ caused by presenilin mutation, the mixed phenotypes of APP mutations, the poor clinical-biochemical correlations for genetic variant carriers, and the failure of $A\beta$ reducing drugs. The amyloid-loss view accounts for recent findings on the structure and chemical features of $A\beta$ variants and their coupling to human patient data. The lost normal function of APP/ $A\beta$ is argued to be metal transport across neuronal membranes, a view with no apparent anomalies and substantially more explanatory power than the gain-of-function amyloid hypothesis. In the loss-of-function scenario, the central event of $A\beta$ aggregation is interpreted as a *loss of soluble, functional monomer $A\beta$* rather than *toxic overload of oligomers*. Accordingly, new research models and treatment strategies should focus on remediation of the functional amyloid *balance*, rather than *strict containment* of $A\beta$, which, for reasons rationalized in this review, has failed clinically.

Keywords: β -amyloid, loss of function, Alzheimer's disease, protein misfolding, metal transport

Introduction

As this is written, every day brings approximately 4000 new cases of Alzheimer's Disease (AD) to the world: Approximately 28–33 million people world-wide suffer from AD[1][2]; in 2010, 21–25 million AD cases were estimated[3] (60–70% of 35.6 million dementia cases), suggesting an annual growth of ~1.5 million cases.

The disease is terrifying to patients and relatives as the gradual loss of memory and identity leads to a slow but steady degeneration of life quality, and the societal costs of AD constitutes a major challenge to healthcare budgets[4][5]. Current treatments delay disease progression by only some months[4][6], and the recent failures of clinical trials of leading drug candidates have been a major concern[7][8][9][10][11][12][13].

AD first manifests slowly, starting with mild cognitive impairment[14][15][16], then leads to gradual loss of cognitive skills, identity, and activity[17][18]. The loss of neurons takes place primarily in the cerebral cortex and in the hippocampus[19]. Definitive AD diagnosis includes deposits of senile plaques outside the neurons and neurofibrillar tangles inside them as two major hallmarks of this disease[16][18]. The senile plaques consist of oxidized and metal-bound β -amyloid ($A\beta$) peptides organized as regular β -sheet-structured fibrils[20][21]. The neurofibrillar tangles consist primarily of phosphorylated tau protein[22][23]. AD patients also bear marks of massive molecular oxidative stress[24], impaired glucose utilization[25][26], diabetes-like pathologies[26][27], and imbalances in metal ion levels, such as calcium[28][29][30], iron[31][32], zinc[19][33][34], and copper[35][36].

The failure to efficiently treat AD directly relates to the fact that AD is a complex, multi-factor late-onset neurological disease: Approximately 95% of AD cases occur with no apparent family history as so called "sporadic AD" (SAD); only about 5% of emerging AD cases can be related to a family history, i.e. "familial AD" (FAD)[37]. The complexity is further reflected in the very broad clinical spectrum of the disease with multiple cognitive, as well as histopathological manifestations[16], the

highly variable clinical features and survival times[9], and the notable fact that age, not any particular gene or event, is the main risk factor of the disease[38], whereas a large range of minor genetic, lifestyle, and environmental risk modifiers contribute to overall disease risk[39][40].

This complexity and the many histopathological aspects of the disease have produced a range of hypotheses on the underlying causes of AD (see **Figure 1**): Focus on the biomolecular changes have led to several "post-translational" hypotheses on the causes of AD focusing on these features[19], e.g. the tau[41][42][43][44], metal ion[45][46] and oxidative stress[47][48] hypotheses. These hypotheses supplement the genetics-supported amyloid and presenilin hypotheses to be discussed below and the early cholinergic hypothesis that emphasized the direct impairment of pathways involving acetylcholine-rich neurons[49][50]. As will be discussed in this review, these hypotheses are *not* contradictory but rather convey specific pieces of information that, when put together in context, provides a unique and consistent picture of the true nature of the disease.

In terms of genetic risk, FAD has been related to variations in the genes coding for the amyloid precursor protein (APP)[51] and the presenilin isoforms PSEN1 and PSEN2[52][53][54][55][56]. Thus, APP and PSEN have been the central frameworks of AD research, leading to two "gene-centric" hypotheses of AD etiology: the amyloid hypothesis[20][57][58] and the presenilin hypothesis[59][60]. In addition, the apolipoprotein E ϵ 4 allele (ApoE4) increases risk by several times for heterozygote carriers and by up to 15-fold for homozygotes[61][62][63]. The sorting protein-related receptor (SORL1 or LR11) has been suspected of being involved in AD for more than a decade[64], and was found to be downregulated in AD [65]. It relates to APP and A β trafficking, and lipid metabolism (it works as a ApoE receptor), putting it in possible relation to other genetic risk factors[66]. In 2007, its gene SORL1 was identified as a likely risk factor of AD[67][68]. Genome-wide association studies (GWAS) have identified a range of other variations that may increase risk of AD[69][70], e.g. *GAB2*, *GALP*, *TNKL1*, *TREM2*, *PICALM*, and *CLU*[54][70][71][72][73].

Figure 1. Simplified overview of the biochemistry of Alzheimer's disease. Previously proposed mechanistic hypotheses are shown in orange and key pathologies in red. APP, PSEN, and Aβ are shown as light blue, green, and yellow, respectively, and metal ions are shown as small green or blue circles. The gain-of-function amyloid hypothesis dominates the left of the figure, and alternative hypotheses are located to the right.

Some established life-style-related risk modifiers are body mass index[74][75][76][77], smoking[78] [79], alcohol intake[80][81][82], diabetes[27][83], hypertension[84], depression[85][86], and overall (both mental and physical) inactivity[87][88][89]. Some risk modifiers reduce risk of AD, including mental and physical activity (e.g. education)[39][90][88], anti-oxidant and vitamin rich diets[39][91][92][93][94]. Several of these risk modifiers probably correlate, so that in summary, an active, healthy, and positive life style reduces risk of AD.

The amyloid hypothesis: Gain of toxic A β function

The senile plaques characteristic of AD have been a natural starting point for understanding the disease: The parallel of protein deposits to Creutzfeldt-Jakob disease led to the original hypothesis that these plaques in AD might be pathogenic[95]. When these plaques were found to contain large amounts of A β peptides, the basis for the amyloid hypothesis was established[96]. Representative structures of the A β monomer in water and the β -sheet-structured aggregates characteristic of senile plaques are shown in **Figure 2 A** and **Figure 2B**, respectively. Subsequently, it was found that A β is produced from APP by the action of β - and γ -secretases[97][98], and moreover, that PSEN is the catalytic unit of the γ -secretase[99][100][101], which also cleaves other important substrates such as Notch[102][103]. Thus, the two major genetic risks of FAD, PSEN and APP, suggested a role of A β and supported the dominating paradigm of AD, the amyloid hypothesis[20][57][104].

The amyloid hypothesis is a "gain-of-function" hypothesis, i.e. it proposes that A β attains a toxic function in the brain that leads to disease[11][57]. In its early form, referred to as the "amyloid cascade hypothesis", it was a *quantitative* gain-of-function hypothesis, i.e. it was assumed that the steady state levels of A β were toxic in themselves, and that these levels were increased gradually during progression of AD[20][104]. This "overload" etiology would provide an explanation for the vast A β deposits in brains that typically represent several years of total A β production[105].

However, various observations were not consistent with a cascade of quantitative build-up as the main culprit of AD: First, neuro-degeneration and cognitive decline does not correlate significantly with plaque A β load[6,11], implying that the plaque load is not a characteristic feature of disease severity. Neuron loss generally begins in specific parts of the brain (e.g. hippocampus) although A β is found across the brain[106][107]. Also, a substantial fraction (perhaps 20–40%) of cognitively normal older people have A β plaques[108] that would satisfy commonly applied AD diagnosis

criteria[109][110]. It has been suggested that these deposits in normal people represent pre-clinical disease states[111], but more likely, the plaques are not involved themselves in the pathogenesis, because they are insoluble and outside the cells: Instead, intracellular soluble oligomers of A β , not fibrils as found in plaques, are the most toxic forms of the peptide[112][113][114][115][116]. Plaques might then in fact be indicators of a protective pathway whereby A β is exported from cells and aggregates into fibrils, to reduce the burden of intracellular oligomers[117][118].

FAD-related mutations in PSEN1 often do not lead to higher, but lower A β levels measured in cultured cells[97][119], which is not consistent with quantitative gain-of-function[9]. The A β peptides produced by cleavage of APP vary in length, with the two dominating isoforms, A β ₄₀ and A β ₄₂, having 40 and 42 amino acids, respectively[9][119]. The APP intracellular domain (AICD) fragment produced simultaneously thus also changes size[120]. Interestingly, PSEN1 mutations generally increase steady-state A β ₄₂/A β ₄₀ isoform ratios, which is therefore now considered the relevant culprit by proponents of the amyloid hypothesis[58][121]. The longer amyloid isoforms have additional hydrophobic amino acids in their C-terminal part and are thus more hydrophobic and prone to aggregation[122][123], and accordingly also more toxic in cell viability assays as these features correlate[20][118][124].

The measured cell toxicity of A β oligomers is very structure-dependent[125][126][127], and it has not yet been possible to identify the specific disordered structural forms of the peptide that allegedly causes AD[128][129], although recently, specific structural features have been found to correlate with toxicity[124]. A number of mechanisms have been suggested[130], such as impairment of long-term potentiation[131] and oxidative stress caused by the peptides[132]. A β forms membrane channels that facilitate calcium transport[133][134][135][136]. The calcium dyshomeostasis thereby caused by A β is a potential mode of pathogenicity[29][30][135][137]. A β may also interrupt copper-mediated prion-protein interaction with NMDA receptors [138] and impair the respiratory chain in mitochondria[139][140][141][142].

Figure 2. **A)** The disordered structure of monomeric A β_{40} in water (PDB: 2LFM)[143]. **B)** The regular β -sheet structure of A β aggregates characteristic of senile plaques (PDB: 2MXU)[144] (Figures were produced using the Pymol software).

The quantitative amyloid hypothesis is thus being abandoned in favor of a "qualitative" gain-of-function hypothesis centering on the A β_{42} /A β_{40} ratio[10][119]. As most FAD-causing mutations increase this ratio[145][146][147][148], it could indeed be pathogenic. The increase in this ratio is probably caused by the fact that γ -secretase cleavage of APP proceeds towards the N-terminal of A β in consecutive steps of 3–4 amino acids[149] and the FAD mutations are likely to affect the precision of this step-wise cleavage[150][151]. PSEN1 mutations tend to be dominant, i.e. heterozygote carriers are likely to develop AD, which has been taken to support a gain-of-toxic function as the compensatory presence of the wild type does not prevent disease[119].

The recent electron microscopy structure of γ -secretase shows details of PSEN1 having a transmembrane helix topology[152][153]. Although the loops are missing in the experimental structure, loops and other missing atoms have been included in full structural-dynamic models in physiologically

relevant membrane environments[154][155] (see **Figure 3A** and **Figure 3B** for full atomic structures of PSEN1 [155] modeled from the 2015 electron microscopy topology[153]). The interior space around the active site constituted by two catalytic aspartates is sensitive to long-range motions caused by dynamic membrane packing effects and loop motions that function as plugs in the transmembrane channel that open access to PSEN1's active site[155]. The gate-plug mechanism suggests that PSEN1 mutations impair membrane packing and thereby substrate selectivity by reducing the steric control of the catalytic site, leading to reduced cleavage precision and increased $A\beta_{42}/A\beta_{40}$ ratios[155]. This mechanism can be directly coupled to clinical outcome: Clinical age of symptom onset of patients carrying PSEN1 variants correlate significantly with increased polarity and loss of stability of the protein[156], consistent with PSEN1 membrane structural integrity as a determining feature of PSEN1-variant caused FAD.

In line with the amyloid hypothesis, drugs have been pursued that prevent the formation of amyloid oligomers, the assumed pathogenic species[157], either by direct molecular interaction with $A\beta$ [158][159][160] or by inhibition of its production[161][162]. Given the potential mechanistic relationship between catalytic proficiency of γ -secretase and the $A\beta_{42}/A\beta_{40}$ ratio, inhibiting γ -secretase could create phenotypes that resemble the FAD-causing mutants; thus, it is hardly surprising that such inhibitors can produce adverse cognitive effects in human clinical trials[13][163]. Instead, *modulation* of the produced relative $A\beta_{42}/A\beta_{40}$ levels is now pursued as one of main clinical strategies in the form of so-called γ -secretase modulators[97][119][161].

Figure 3. All-atom structure of mature presenilin 1 with loops from homology models and molecular dynamics simulations[155], based on the partial presenilin coordinates of the 2015 electron microscopy structure of γ -secretase[153]. **A)** Seen from the in-membrane perspective; **B)** seen from the above-membrane perspective. The catalytic aspartate residues D257 and D385 are shown in red. The loops play a major role in controlling access to the protein's interior.

Challenging the amyloid hypothesis

Recently, the $A\beta_{42}/A\beta_{40}$ ratio and specific chemical properties of PSEN1 mutants have been shown to correlate significantly with clinical symptom onset[156], providing a first relationship between human AD and protein-chemical features, which complements data from cell and mouse models that provide poor correlations to clinical data in meta-analysis[9] and in the transition to human trials[7][163]. Yet, correlation does not imply causation, and a complex disease such as AD features many apparent correlations. One example is the $A\beta_{42}/A\beta_{40}$ ratio: While this ratio *does* indeed correlate inversely with human symptom onset for the PSEN mutations[156], it does not for the phenotype-wise mixed APP mutations[9], and the increased ratio in PSEN mutant phenotypes could thus simply be a reflection of the loss of function of PSEN as the true cause of disease. Thus, all relevant correlations and equally

well all *lack* of correlations must be viewed in their totality. More generally, the following issues challenge the amyloid gain-of-function hypothesis:

First, it remains unclear how the curious $A\beta_{42}/A\beta_{40}$ ratio defines disease, while total levels of $A\beta_{42}$ do not (total levels tend to decrease or change insignificantly in PSEN1 mutant phenotypes[9][148]). Presumably, higher $A\beta_{42}/A\beta_{40}$ ratios either lead to more oligomers or impart them with more sinister properties, yet how can the ratio, but not $A\beta_{42}$ alone, produce such an effect? Lower overall production of $A\beta$ caused by PSEN1 mutation does not necessarily imply lower steady-state levels of the presumed pathogenic oligomers, if oligomer clearance rates are lowered even more. Both $A\beta_{42}$ and $A\beta_{40}$ clearance has been found to be reduced by 30% in SAD, while production was unaffected[164]. This could imply that steady-state $A\beta$ pools are increased in SAD, but this is inconsistent with the reduced levels seen in PSEN1 mutants[146]. Thus, it probably rather reflects the increase in degradation-resistant plaques, whereas intracellular soluble $A\beta$ may have decreased: This would explain the lower clearance rates measured and reconcile the data discussed above.

The oligomers may be more degradation resistant than monomers, but probably less than the tightly bound β -sheets of plaques. The amyloid hypothesis does not explain how the PSEN1 mutant phenotypes with commonly observed lower steady-state levels of $A\beta_{42}$ could still lead to more pathogenic oligomers. In this author's view it would require that i) physiological oligomers are hetero-oligomers consisting of mixtures of $A\beta_{42}$ and $A\beta_{40}$; such hetero-oligomers have been studied by Pauwels et al.[165]; ii) local surplus of $A\beta_{42}$ seeds $A\beta_{42}$ -enriched hetero-oligomers that may be more pathogenic and plausibly more resistant to degradation than oligomers of lower $A\beta_{42}$ content, so that the clearance is reduced to increase the steady-state pool of pathogenic oligomers. This competitive seeding mechanism could explain why a larger $A\beta_{42}/A\beta_{40}$ ratio, but not the total $A\beta_{42}$ levels, may cause disease.

Second, it is a shortcoming of the amyloid hypothesis that the *normal functions* of A β and APP and, for that matter the other APP products, sAPP α and AICD[120], are not accounted for: APP-related proteins are merely viewed as pathogenic, yet the elaborate splicing of APP is clearly there for a reason, and there is substantial support for a physiological role of A β [166][167][168][169]. In addition, AICD regulates transcription in a way that somewhat resembles that of the intracellular domain of Notch also produced by γ -secretase[170]. These functions of cleavage products further complicate the strict amyloid gain-of-function hypothesis[47]. Specifically for A β , concentrations below nano-molar (as encountered within cells) are neurotrophic whereas only high concentrations (typically micro-molar levels as seen in cell assays) are toxic[168][171]. *This suggests that there is a therapeutic window of A β levels that should be stabilized, rather than merely reduced.*

Third, current research models of the amyloid hypothesis rely on measurements of A β toxicities[172] and aggregation tendencies[173] occurring at micro-molar concentrations, corresponding to ~1 year of total brain production, 1000-fold higher than the biologically relevant concentrations[174][175]; yet AD is age-dependent and gradually develops over years. Some toxic modes associated with physiologically relevant concentrations have been reported[126][176], but the toxic mechanism of A β oligomers remains debated[130][177].

The amyloid hypothesis lends support from APP mutations that cause AD, and specific A β variations are widely heralded as confirming the amyloid hypothesis, a notable example being the recently identified protective A2T variant[178]. **Figure 4** shows the sites of A β mutation and cleavage in APP. Attempts to link clinical phenotypes (protective vs. pathogenic) to actual biochemical properties are being made, with particular focus on the effect on APP cleavage, and thus A β production, and aggregation tendencies[179]. However, data from APP mutant models are mixed[180][181][182]: Some cases show normal behavior despite high amyloid levels[183], while impairments resembling AD features can be induced by other features such as metabolic deficiencies[184].

Figure 4. The A β region of APP. Cleavage by α -, β -, and γ -secretases is shown in green, and disease-related mutations are shown in red.

Furthermore, meta-analysis shows that reported biochemical data for A β variants are disturbingly heterogeneous: Published amyloid levels and A β_{42} /A β_{40} ratios measured in cultured cells, toxicities from cell viability studies, and aggregation propensities from thioflavin T assays for these variants scatter to the extent that conclusions based on any one or even several of these variants are statistically meaningless and thus do not support the "quantitative" amyloid hypothesis[9]. Distinct toxicities of A β variants expressed in cell lines do correlate with their aggregation tendencies in *cell assays*[118][124]. Yet, while the relationship between cell toxicity and aggregation propensity is strong[118], these toxicity and aggregation data do not correlate to *human clinical data* of A β variant carriers at all[9]. Thus, at best, data from cell and mouse models are too heterogeneous to give insight into human disease, at worst, they are fundamentally unrelated to the disease[9].

Fourth, the APP mutations are even more problematic than the biochemical heterogeneity would imply: Different mutations in APP produce distinct histopathologies and different intensities of tangles and plaques as typified by cerebral amyloid angiopathy (CAA) vs. classical AD; some variants lead to increased, others to decreased total A β levels; variants such as A2V, H6R, D7N (using the A β numbering scheme) produce A β_{42} /A β_{40} ratios similar to wild type APP, whereas APP variants E22G, E22K, and E22Q *lower* this ratio; and average clinical ages of symptom onset vary from the *thirties* to

the *sixties* of age[9]. *In conclusion, the biochemistry of APP mutations provides no evidence of gain of function and does not explain variations in clinical outcome.*

A fifth point of concern is that while it is thus increasingly clear from correlation studies that the A β variants tell us little about disease[9], the *PSEN1 variants* tell us a lot[156]. Many more mutations in PSEN1 than in APP cause AD, although APP contains the final A β product[59], and the PSEN1 mutations have chemical properties that have now been directly correlated to clinical FAD characteristics[156]. These PSEN1 mutations cause lower γ -secretase activity and reduced production of A β ; this could suggest that PSEN1 is more central to AD than A β is[185]. The PSEN1 mutant phenotypes are much more clinically and biochemically homogenous than are the APP phenotypes, as they produce classical AD phenotypes and tend to increase A β_{42} /A β_{40} ratios in most cases[186]. The A β_{42} /A β_{40} ratios correlate with actual human clinical data[156]. Thus, a competitive seeding mechanism that would lead to gain of toxic oligomers *could* be a determinant of human AD as cell and mouse models do not capture such a mechanism. Yet, it could equally reflect loss of functional monomeric A β , to be explored below.

Sixth, the other important histopathological features of AD, e.g. metabolic deficiencies, massive post-translational modifications, metal ion imbalances, and oxidative stress, are not accounted for in any current version of the amyloid hypothesis [19]. It is unsatisfactory that the amyloid hypothesis does not explain the main risk factor of disease (age) as emphasized by e.g. the two-hit hypothesis[187]. The aging human proteome is *the* relevant framework for understanding AD. The aging proteome exhibits down-regulation of genes involved in synaptic function, including calcium homeostasis and signaling, and vesicular transport, and upregulation of anti-stress and anti-inflammation genes[38]. The amyloid hypothesis, founded very much on the FAD mutations in PSEN1 and APP, does not explain the vast majority of sporadic AD cases, where no such A β -related genes seem to be strongly involved.

Finally and most importantly, the amyloid gain-of-function hypothesis has so far failed utterly in its attempts to produce a cure or even halt of AD[7][11]. The clinical human data have not confirmed the supposedly promising data from cell and mouse models used to research the drug candidates of the main pipelines[13][163], consistent with the poor correlations between human clinical data and these types of data models that is already clear from meta-analysis[9]. In fact, clinical trials essentially disprove the quantitative gain-of-function hypothesis[6][12][188][189], but perhaps not a *qualitative* gain-of-function mechanism centering on specific local pools of A β ₄₂-enriched hetero-oligomers. The following should be noted:

(i) *Active* A β immunization with AN1792 produced cases of brain inflammation and continued cognitive decline[190], and no such treatment strategy has produced favorable Phase 3 outcomes[180];

(ii) *Passive* A β immunization with Solanezumab showed no improvement in cognitive function in the two major phase 3 trials[191]; however subsequent analysis of the combined data revealed a positive effect on cognition[192][193]. Also, Bapineuzumab did not show any benefits[194] and can produce adverse effects vs. placebo[195] *despite* lowering amyloid levels[196]. Gantenerumab is currently being continued despite reports of inflammation[197]. Since the antibodies bind differently to A β , they may affect the functional monomer pool and the oligomer pools differently, and in principle, this may be a useful way to reconstitute functional loss of A β monomers.

(iii) Both the γ -secretase inhibitors Avagacestat and Semagacestat that reduce A β production have shown adverse cognitive side effects, and were discontinued[198][199]. While this has been interpreted as possibly due to impairment of Notch signaling and other adverse effects of reduced PSEN proficiency, the immunization data are more consistent with loss of A β function in the light that a therapeutic window of neurotrophic A β levels are well-established[168][171] and since these strategies do not impair other functions of PSEN1. Instead, *both* adverse clinical outcomes of passive immunization and γ -secretase inhibition can be explained by loss of function.

The gain vs. loss of function hypotheses are summarized in relation to some central data in Table 1. The possibility of a loss of function mechanism will be explored in detail in the remainder of this review.

Table 1. Observations related to AD can be explained both as gain or loss of A β function^a.

Observation	Explanation, gain of function	Explanation, loss of function
Aggregation	oligomers are toxic by some specific mechanism	oligomers represent loss of functional monomer
PSEN1 mutant phenotypes	high A β_{42} /A β_{40} ratios increase A β oligomer pool or specific toxicity, even if total A β_{42} levels decrease	less produced A β represents loss of function; however, increased oligomerization reduces functional monomer pool
APP mutant phenotypes	mixed phenotypes cannot be consistently explained. Some affect APP cleavage to increase, others to reduce A β levels	N-terminal mutants lose metal-binding; C-terminal and over-expressing mutants aggregate and lose monomer pool
Toxicity upon overexpression of FAD mutants	oligomers are toxic by some specific mechanism	depletion of metal status in cells
adverse effects of γ -secretase inhibitors	due to lack of selectivity and Notch impairment	due to reduced functional A β levels, as in PSEN1 phenotypes
adverse effects of passive A β immunization	not targeting the right form of A β	due to reduced functional A β levels
Positive effects of some A β antibodies	removing pathogenic oligomers	reconstituting functional monomers
Oxidative stress and metal dyshomeostasis	possible toxic modes of A β -metal interactions	directly related to APP/A β function (loss of A β function causes copper buildup in cells)

^a See text for discussions and specific references.

Moving forward: What does the structural chemistry of A β peptides tells us?

While the heterogeneity in *clinical* data is due to disease risk modifiers, the substantial heterogeneity in *biochemical* data for A β variants, such as measured aggregation tendencies from thioflavin T assays, is due to different lab protocols and the special chemical features of A β [9]. Efforts are ongoing to produce consistent, stable, and reproducible monomeric and oligomeric A β samples that will remove some of the protocol-based heterogeneity[200][201][202]. However, even beyond the sample management issue, the structural variability of these highly disordered peptides[203] renders observed properties such as toxicity very conformation-dependent, and, since conformation is very dependent on chemical environment, *A β structures and their derived toxicities are highly sensitive to concentration, pH, ionic strength, co-solvents, and the time scale of the experiment performed*[118][204].

Identifying the physiologically relevant structures of the A β monomer is a necessary prerequisite to understanding both its oligomerization and potential gain of pathogenic action, but also its natural roles[9][20][123][205] such as membrane interaction[206][207]. In water, the free A β monomer has a disordered coil-dominated structural ensemble with some helix and little β -strand[203][208][209][210]; this is consistent with available nuclear magnetic resonance (NMR) and circular dichroism (CD) spectroscopic data on the monomer and reflected structural models with PDB codes 1BA4[211], 1IYT[208], 2LFM[143], 1Z0Q[209], and 1AML[212].

In co-solvents and close to membranes, the helix content of A β monomers increases[212], due to the helix dipoles being stabilized in low-dielectric environments[213]. The shape-shifting nature is illustrated by two representative structures deduced from NMR data in **Figure 5A**, showing the A β structure in water, and **Figure 5B** showing the structure of A β in a membrane-mimicking chemical environment; in the latter case, the C-terminal of A β has become an extended, potentially membrane-spanning helix, an observation that fits well with the widely documented membrane channel properties of A β [134][136][214].

Figure 5. The shape-shifting nature of A β : **A)** NMR-derived structure of A β_{40} in water (PDB: 2LFM)[143]. **B)** NMR-derived structure of A β_{40} in a micelle membrane-mimicking environment (PDB: 1BA4)[211]. The hydrophilic N-terminal is shown on top, whereas the hydrophobic C-terminal, which forms helix in the membrane-environment, is shown to the lower right in both cases.

On the other hand, if the monomer A β is subject to other chemical interactions or modifications, such as high A β concentration, contact with metal ions[215][216][217][218][219] or genetic mutation[220][221], it forms oligomers and fibrillar aggregates. In these structures, the peptide converts structure from helix-coil to the extended sheets of β -strands found in senile plaques, as seen in **Figure 2B**[209]. As an example of the relevance of time scale, Abelein et al.[222] found mainly coil, some indications of helix, and no β -strand in the pure A β_{40} monomer, but after days at room temperature they observed β -strand characteristic of aggregated peptide[222]; the fibrils making up the senile plaques consist mainly of such extended sheets, packed with metal ions[209][223][224].

Considering the major structural variability of A β occurring both *in vitro* and *in vivo*, attempts have been made to identify the "physiologically relevant" ensembles of the peptide, by correlating specific structures directly to human clinical outcome and cell toxicities. This provided the first statistically significant relationships between fundamental chemical properties and clinical and biochemical phenotypes[118][124][213]: Remarkably, hydrophobic exposure in the most disordered structures of A β correlate with features of the human disease, i.e. the diagnosis age of patients carrying a specific variant, whereas other structures do not. This could suggest that the coiled disordered structures with a small (<25%) helix segment are the physiologically relevant forms of A β [213].

The differences in experimental toxicities of genetic A β variants are well explained by each variant's conformational ensemble: Specifically, toxicity correlates with the extend of hydrophobic exposure of disordered structural parts of the variants, providing a detailed molecular picture with statistically significant correlations to experimental toxicity data[118][124]. Thus, A β aggregation and cell toxicity is caused by hydrophobic exposure in specific disordered amyloid states that can be targeted by molecular intervention, e.g. antibodies[158][160]. However, in the light of the poor correlation between toxicity assays and clinical disease features[9], the question still remains whether this oligomerization-driven cell toxicity has anything to do with AD.

Evidence for normal physiological functions of APP/A β

Mouse knock-out experiments indicate that APP-related proteins have physiological roles: APP-knockout alone reduces synaptic proliferation, whereas single-knockout of the related amyloid precursor-like protein 2 (APLP2) does not affect neuron function and morphology[225]. However, knockout of *both* APP and APLP2 simultaneously is lethal and indicates an important role of APP/APLP2[226][227] and that each protein can compensate the absence of the other[228]. Although these proteins are unimportant for cell differentiation[229], they affect synaptic plasticity under normal

conditions[230] and are essential for hippocampus function and spatial learning of mice[231]. The role of APP or its cleavage products is also seen from its importance in resisting kainite-induced seizures[232]. The APP family of proteins are mainly important in aged, not juvenile mice[227]. Consistent with these experiments, several roles of these proteins in maintaining synapses have been identified[233][234].

A β produced from APP also has a normal function in cells: The work by Yankner et al.[171] is often cited by proponents of the gain-of-function amyloid hypothesis as evidence of toxicity. However the work actually found beneficial effects of the peptide at lower concentrations, but toxic effects at higher concentrations[171]. Plant et al. have confirmed this by different lines of investigation, showing that inhibition or depletion of A β_{40} by either secretase inhibitors or A β antibodies is lethal to cultured neurons, and A β_{40} is protective in a concentration-dependent way, whereas A β_{42} was not[235]. A β depletion also impairs neuronal activity in mice[166]. Important hints to the nature of this function comes from work showing that A β monomers protect against copper- and iron-induced toxicity[167] and play a natural role in regulation of vesicle release in hippocampal synapses, with more extracellular A β related to increased release probability[169].

These various findings indicate that loss-of-function is a real peril that must be accounted for, and the studies therefore anticipated the negative outcome of strict γ -secretase inhibitors such as Solanezumab ten years later[198]. At that time, the impaired proficiency and reduced A β levels of FAD-causing PSEN1 mutations were also well known, further mystifying the rationale behind the quest for strict A β containment. This is a remarkable example of the inability of scientific paradigms to rationally self-correct, but it also reflects negatively on the R&D management of major companies who were obsessed with the toxic side of the therapeutic A β window while ignoring the neurotrophic side; this has, unfortunately led to a waste of research (and shareholder) funds, and more importantly, to a delay in the testing of drug candidates that could be truly efficient[163][236]. *And still today, research*

and drug development efforts do not present a balancing strategy of $A\beta$, despite evidence summarized above that such a balance is necessary.

Figure 6. Zinc sites (zinc shown in yellow) in key proteins relating to Alzheimer's disease: **A)** $A\beta$ based on the NMR structure 1Z09.pdb[237]; **B)** the crystal structure of the E2 domain of APP (3UMI.pdb)[238]; **C)** ADAM17 as a representative of the ADAM family of zinc peptidases with α -secretase activity, based on the structure 3LE9.pdb[239]; **D)** Loss of metalloprotein function contributes substantially to the pathology of Alzheimer's Disease. Insulin degrading enzyme is one of several $A\beta$ -degrading zinc peptidases that will lose function upon metal dyshomeostasis (figure made from coordinates in the reported crystal structure 2WK3.pdb[240]).

The natural function of APP: Metal binding and transport

In the following, it is argued that the normal physiological function of APP/A β is regulation of intra-neuronal relative copper levels via low-to-moderate affinity divalent metal transport. The theory that metal ion imbalances play a role in AD is well-established[19][34][46], and in particular calcium has been associated with AD for three decades[241] and reviewed in detail[28][29][135][137][242][243]. Most of the proteins central to AD have copper or zinc sites, with some examples shown in **Figure 6**[19][244]. Evidence for APP as a metal transport protein includes the following:

i) First, APP has multiple established metal binding sites[245][246][247][248]. The large extracellular part of APP is generally divided into two domains, E1 and E2 : E1 consists of the growth-factor like domain that contains a heparin binding loop [247] and the copper-binding domain (CuBD)[249][250] consisting of His151, His147, and Tyr168[249][251]. The affinity for copper is moderate, approximately 10 nM[246]. There is also a Zn(II) site within residues 181–200[252]. Several Cu(II) and Zn(II) sites are present in the E2 domain of APP-like proteins reported to regulate conformation and possibly function[238][253].

ii) APP reduces bound Cu(II) to Cu(I) in association with electron transfer and disulfide bond formation[254]. The combination of copper binding sites and this redox chemistry has been suggested to imply that APP transports Cu(I) across the membrane in analogy to other copper-transporting proteins having membrane-associated copper binding sites that reduce Cu(II) to the transportable Cu(I) oxidation state, e.g. the plasma membrane copper transporter Ctr1, which is cleaved from the membrane upon high copper status to prevent uptake of copper[255].

iii) Knockout of APP in cultured neurons leads to reduced Cu(I) induced toxicity in neurons[256], suggesting that APP is essential for neuronal copper uptake. In addition, overexpression of APP leads to intracellular copper deficiency and overexpression of the A β -containing C-terminal fragment of APP leads to both copper and iron deficiency in mouse brains[257]. Copper efflux function

due to APP can be reduced by copper chelating ligands[258]. The specific copper-binding domain of APP has been shown to reduce toxicity from copper exposure[259].

iv) Other researchers have found[260] that increased copper exposure in aged mice leads to A β accumulation and down-regulation of low-density lipoprotein receptor-related protein 1 (LRP1) – a transporter of A β [261] that also controls APP trafficking and processing[262][263].

v) Buxbaum et al. found 20 years ago that APP cleavage is regulated by increases in either protein kinase C or calcium levels independently[264]. Secreted forms of APP have been found to protect against excitotoxicity and reduce calcium levels in cells[265]. Addition of the 105-residue C-terminal fragment of APP to cultured cells has been found to increase intracellular calcium levels and make rat cortical neurons more prone to glutamate-based excitotoxicity; calcium levels could, interestingly, be reduced by cholesterol[266]. The C-terminal fragment is neurotoxic both with and without the A β sequence fragment included[267].

vi) APP stabilizes the Fe(II) exporter ferroportin and has been suggested to be analog of ceruloplasmin (a copper- and iron transport protein that interacts with ferroportin) although it does not have ferroxidase activity as initially suggested [268].

A β : A metal ion transport peptide

If APP is a membrane protein that controls certain aspects of intra-neuronal metal status, the question is, how does it do so? One answer to this question is by its intrinsic ability to bind and respond to metal ions within the membrane, as summarized above; the other is by the use of its splicing product, the A β peptide. The evidence for such a mechanism is now presented:

i) First of all, A β is itself a genuine metal-binding peptide with an archetypical N-terminal metal-binding site constituted by three histidines (His-6, His-13, and His-14 using A β numbering, see **Figure 4**)[269][270]. Metal ions such as Cu(II) and Zn(II) mostly form 1:1 complexes with A β ,

sometimes with a secondary, low-affinity binding site[248][271][272][273]. The binding of metal ions to A β changes its structure and induces formation of fibrils[272][274]; these metal-rich fibrils resemble the senile plaques characteristic of AD.

ii) Furthermore, A β is also an archetypical *amphiphile*: It has a hydrophilic N-terminal region with established metal binding properties and a hydrophobic C-terminal region providing its membrane affinity[19]. This amphiphilic design seems ideal for micelle- or membrane-channel formation.

iii) As the apo-A β carries a charge of -3 , binding of metal ions of positive charge $+2$ or $+3$ would increase A β hydrophobicity and most likely also its association with membranes[213].

iv) The A β monomer is disordered in aqueous solution but forms helix structures in low-dielectric environments such as co-solvents and micelles, thus providing a structural rationale for its membrane channel function[135][214][275][276], not simply as a toxic mode of A β action but as a potential natural function of the peptide.

In summary, the “shape-shifting” nature of A β , the increased helix forming tendency in membrane environments, its metal-binding properties, and the amphiphilic chemical features (hydrophilic N-terminal half, hydrophobic C-terminal half) indicate that the peptide has evolved to interact with metal ions and cell membranes as part of its natural function.

Indeed, such a function has been observed: A β forms channels that enable calcium transport through membranes[135][136][277][278][279], and these channels can be blocked by zinc[207][214]. Also, the loss of cellular copper causes copper depletion in the highly abundant cytosolic anti-oxidant protein SOD1 that plays a central role in amyotrophic lateral sclerosis (ALS) which shares many similarities with AD[19][280][281]; dietary copper compensates this loss and reduces A β production[282].

Regulation of the APP/A β metal transport system: Enter secretases

As evident from the research summarized above, APP and A β are genuine metal proteins and metal peptides, respectively, having strong association with membranes and direct effects on intra-neuronal metal status. However, the mechanism by which such an APP/A β system senses and regulates metal status remains to be explained. I argue here that this regulation mechanism works via the much studied (in the different context of amyloid production within the amyloid hypothesis) splicing of APP by the α -, β -, and γ -secretases.

i) First, β -site APP cleaving enzyme 1 (BACE1), the aspartyl protease that initiates production of A β by cleaving its N-terminal from APP[283], contains a copper site, and overexpression of BACE leads to reduced SOD1 activity consistent with loss of intracellular copper (copper availability is required for proper holo-protein SOD1 folding and activity)[284][285]. This suggests that BACE activity somehow reduces copper status in neurons. Hou et al. showed that not only does copper exposure lead to increased APP expression and A β formation, it does so by action of a copper sensing protein (CUTA) that directly interacts with the β -cleavage site of APP[286], and recently, Multhaup's group showed that the transmembrane region of BACE1 contains a genuine, highly conserved cysteine- and methionine-rich copper binding site, which loses copper binding affinity upon mutation of cysteine to alanine[287]. Supplementing this evidence, Gough et al. showed that N-terminal archetypical metal-binding site of A β , which is also the β -cleavage site, constitutes the actual site that regulates β -secretase cleavage of APP[288]. These various data strongly suggest that BACE1 is activated by copper levels by specific copper binding to facilitate cleavage of APP.

ii) A variety of metal chelators reduce amyloid plaque formation[289], down-regulate APP expression and lower A β secretion as a response to the depletion of the intracellular free copper pool[290]. Strong metal chelators such as EDTA reduce γ -secretase activity and thereby, production of

A β , consistent with a reduction of intra-neuronal metal status directly down-regulating A β -producing γ -secretase activity[291]. Zou et al. found that the beneficial effect of monomeric A β in protecting against metal-induced oxidative stress toxicity resembles that of classical non-natural metal chelators such as EDTA[167].

iii) Inhibition of copper transporters increase A β in brain lysates and decrease expression of A β -degrading proteases [292].

iv) Copper-induced toxicity in rabbits leads to learning impairment and to enhanced A β plaque formation, suggesting that production of A β from APP increases with metal status[293].

A consistent explanation of these observations is that high copper status is counteracted by activation of the amyloid-producing secretases, leading to cleavage of APP and production of the copper-transport peptide A β , which is then exported out of neurons to produce the metal-enriched plaques that characteristically define AD in human brains. *Thus, APP/A β is probably a neuronal metal transport system, with the spliced A β peptide working as an exporter in combination with the low-density lipoprotein receptor family of proteins. The widely studied cleavage of APP by α -, β -, and γ -secretases to produce A β is therefore suggested to be a regulation mechanism of neuronal metal status.* It is notable that by analogy, the plasma membrane copper transporter Ctr1 is also cleaved from cell membranes: Its cleavage is a result of high copper load, to prevent copper uptake[255].

Observing the chemical composition of senile plaques, with their massive co-location of copper, zinc, and iron ions[209][223][224], they might be referred to as amyloid-metal deposits rather than simply amyloid deposits. These plaques are non-pathogenic[107][108], and the aggregation propensity of amyloid variants does not correlate with disease severity[9]. Why then do we see this buildup of plaques if not as part of the pathogenesis itself? The alternative answer is: Either as an irrelevant downstream consequence of the true pathogenesis, or due to a protective mechanism related to disease. Within the view presented here, these metal-enriched plaques are a natural result of excessive metal

export from the neurons via A β , a metal-binding amphiphilic membrane-associated peptide plausibly evolved specifically for this purpose.

Accordingly, the ability of metal ions to bind and induce A β aggregation[19][46][217][218][219][294], which has so far been interpreted as a *toxic mechanism* of metal-A β interaction, can instead be explained as a physiological metal-A β interaction and metal-export-deposit function. The observations of beneficial effects of metal chelators on A β status in cultured cells[295][296] and in *Drosophila* that expresses human A β [297], and on the cognition of mice[298] as a result of the reduced intracellular copper levels and concomitant reduced A β production, are all in line with the regulation mechanism suggested above.

Aggregation causes loss of functional A β monomer

It may seem ironic to a community accustomed to the gain-of-toxic-function amyloid hypothesis to think of the opposite scenario, loss of normal A β function. However, the main observations in support of gain of function are equally consistent with loss of function, whereas various other observations are *mainly* consistent with loss of function.

First of all, accounting for the normal beneficial functions of A β ₄₀[166][167] should be expected even of a gain-of-function mechanism, yet the gain-of-function hypothesis does not do so, despite the established normal functions. Gain of function is usually attributed to the PSEN1 and APP genetic mutations because they are mostly autosomal dominant[299][300]. The gain of function is supposed to arise from an increase in quantity or malicious quality of A β oligomers by means of aggregation processes, consistent with mostly autosomal dominant mutations[117][133]. As the total A β pool consists of innocent, functional monomers and pathogenic non-functional oligomers, oligomerization implies a depletion of the pool of functional A β monomers concomitant with an increasing oligomer pool. The dominant FAD mutations can therefore equally well cause disease by

loss of A β function, since the heterozygote's wild type A β cannot protect itself against aggregation and thus, depletion of the overall pool of A β monomers.

Loss of A β monomers is consistent with the fact that *total* A β levels decrease in most FAD-causing mutants[146][185], whereas gain of function requires a specific mechanism driven by increased local A β_{42} /A β_{40} ratios, as discussed above (*competitive seeding*). Most of the genetic risk factors of FAD are now known to reduce soluble monomer A β_{40} levels either directly[185] or by increased aggregation: A β_{40} production is in some cases halved by PSEN1 mutations [301], and if the A β_{42} /A β_{40} ratio causes aggregation, this would equally constitute a substantial loss of the normal functions of A β [302]. Typical A β deposits in senile plaques correspond to perhaps 5–10 years of total A β production, or about seven years calculated recently[105]. Rather than implying, as commonly done, that these plaques represent a *toxic overload* of A β , clearly, the documented functions of A β will be affected by such a massive deposition.

Metal homeostasis and AD

Dyshomeostasis of calcium, zinc, iron, and copper levels is an established pathological feature of AD[19][31][34][46][216][243][303], as probably first suggested in the case of zinc by Burnet[304]. The massive metal-enrichment in senile plaques[46][270][305] was a hint of this, but it is more specifically seen from upregulation of metal transport proteins in APP/PSEN1 mutant expressing mice[306][307] and upregulation of zinc transporters[306][308] and metallothioneins[309] in AD patients. The heterogeneous data on metal status in AD brain parts can be reconciled by a mechanism whereby metal ion status is perturbed from the *bound* pool in proteins to the *free* pool in the cytoplasm; this shift has many biochemical consequences[19].

While metal imbalances could be a consequence of general neurodegeneration and thus not causative, there is support for a causal role[19][46]: One example is the "zinc cascade", zinc's control

over the A β balance via zinc peptidases involved both in A β formation and degradation[19]. Cleavage of APP at the α -cleavage site, which lies within the A β region and thus prevents amyloid production, is catalyzed by membrane zinc-proteases of the ADAM family (A Disintegrin And Metalloprotease family)[310][162] (**Figure 4C**). A β is rapidly degraded by a number of proteases[311], notably neprilysin[312][313], angiotensin-converting enzyme[314], matrix metalloproteases[315][316][317], and insulin degrading enzyme[318][319] (**Figure 4D**). As previously pointed out[19], *all of these are, curiously, zinc proteases*. Impairment of some of these proteases can be related to AD[317]. If zinc dyshomeostasis manifests as loss of functional protein-bound zinc pools, these zinc enzymes would be impaired, providing a direct causal relationship between zinc homeostasis and amyloid balance[19].

The homeostasis of the three divalent metal ions calcium, copper, and zinc is tightly controlled due to the narrow window between nutritional value in important proteins and toxic nature in free form[320]. Dependent on their mutual concentrations, they serve in neuron signaling, apoptosis, inflammation, oxidative stress control, and cell proliferation: In particular, life-death processes of cells are controlled by calcium[321][322][323] and zinc levels[324][325][326], and zinc plays a central role in the apoptosis, oxidative stress, immune defense, neurogenesis, and synaptic plasticity[327][328]. Calcium-regulated life-death choices work through transcription factors such as MEF2[322], which are also risk factors of AD recently identified from GWAS[73].

Their homeostasis is intimately linked and synergistic[329]: The zinc-regulated life-death choices are regulated by oxidative stress and are coupled to copper levels and metallothioneins[330]. Increased cytoplasmic zinc levels elevate calcium levels and activate calcium-dependent signaling pathways that lead to death[331]. Notably, zinc also inhibits Notch signaling[332], which modulates cellular life-death decisions *via* zinc finger transcription factors, and this mechanism provides one of several pathways that unify SAD and FAD, with PSEN1 phenotypes having genetically impaired Notch

signaling due to PSEN1 mutation, where zinc overload provides a sporadic counterpart of impaired Notch signaling.

The metal ions need to be treated differently and are heterogeneously distributed in the brain[333]: Copper is redox-active and binds more strongly to the nitrogen donor ligands of APP and A β , which can be explained from the Irving-Williams series of chemical binding constants[19]. Copper is particularly enriched in the hippocampus where AD typically starts[334]. In contrast, calcium and zinc are redox-inactive but calcium is oxophilic and preferably binds to oxygen-donor ligands, whereas zinc also binds nitrogen- and sulfur-donor ligands; they also differ in terms of cellular distribution and abundance: Calcium is most abundant, whereas zinc is abundant in vesicles of zinc-enriched neurons, transported by ZnT3 transporter proteins[335][336], and zinc is deposited in AD patients together with plaques, around impaired blood vessels, and in cells with tau pathology[337], with significantly increased levels in hippocampus of AD patients[338].

Copper is used in active sites of enzymes such as cytochrome c oxidase of the mitochondrial respiratory chain and SOD1[19]. Loss of functional copper would lead to impairment of the respiratory electron chain and mitochondrial energy inefficiency, increased oxidative stress and potentially apoptosis of the neuron; thus metal dyshomeostasis can cause mitochondrial dysfunction characteristic of neurodegenerative diseases[19]. SOD1 is located on chromosome 21 like APP and plays a key role in zinc/copper homeostasis and oxidative stress control in the vulnerable neurons with their high oxidative metabolism[339]. Mutations in SOD1 is a major genetic risk factor of familial ALS[340][341]. Another gene on chromosome 21, Down syndrome critical region gene 1, produces cognitive deficits and inhibits Calcineurin's calcium-dependent phosphatase function[342], which contributes to the neurological impairment characteristic of trisomy 21. Copper dyshomeostasis is well known to be neuropathological as evident from e.g. Menkes and Wilson's diseases[343][344].

Based on the available evidence summarized so far, it can be suggested that *APP/A β controls secondary metal level balances, notably the Cu/Zn ratios, and, in combination with presenilins, the Cu/Ca ratio*. This is consistent with the moderate affinity of the metal sites in APP[246] and A β [19]; metal transporters generally separate into high- and low-affinity types based on their role, and low-to-moderate affinity seems suitable for ratio maintenance, whereas high-affinity transporters control primary import and export[345]. The APP/A β is thus most likely a secondary metal transport system with metal ion selectivity: For example, copper is known to bind 2–3 orders of magnitude more strongly to A β than zinc[19]. *This implies that the main function of APP/A β is to balance relative intra-neuronal metal levels.*

The proposed function of APP/A β and its loss-of-function role in AD is supported by the findings that presenilins induce copper and zinc uptake[346], while they leak calcium[347][348]. This indicates that presenilins are involved in maintaining Cu/Ca and Zn/Ca ratios. APP's established dimerization equilibrium and its proteolytic processing[349] may thus be a mechanism to control Cu/Zn and Cu/Ca levels in neurons; this dimerization of APP and associated A β production is facilitated by copper levels[350]. The processing of APP by presenilin-containing γ -secretase has recently been suggesting to be directly coupled to channel formation in presenilin, so that APP cleavage and channel activity may be linked[155].

As discussed above, there is evidence that metal binding at the archetypical N-terminal A β site within intact membrane-bound APP triggers APP cleavage and production of A β . Possibly, although speculative, the formed metal-A β peptides then use the instantaneously formed pores in presenilin to immediately exit the membrane after they have been produced by APP cleavage. This mechanism would explain why A β cation-selective channels are inhibited by zinc[206][207][214], an unusual property if not enabled to ensure metal ion selectivity of the APP/A β system. This "made-to-go"

mechanism would provide a pathway for extracellular deposition of metal-enriched senile plaques and explains why zinc exposure increases A β production from APP and leads to A β deposits[351].

CAA vs. AD: An explanation based on normal A β function

An important piece in the puzzle is the observation that genetic A β variations (see **Figure 4**) located within the N-terminal 1–16 region tend to give rise to classical AD phenotypes, whereas mutations within the C-terminal part of A β beyond position 20 cause CAA, e.g. the Dutch, Italian, Flemish, Arctic, and Iowa variants[9]. Also, all the FAD-related APP mutations that increase total amyloid levels are located in the N-terminal half of the peptide[9]. No one has provided an explanation for these differences. The common argument from the amyloid gain-of-function paradigm is that these mutants affect α -, β -, and γ -cleavage of APP in different ways: Clearly, the mutants are located in the neighborhood of these APP cleavage sites, and the Swedish double-mutation at the β -site (but outside the A β sequence) supports this view as it leads to large quantities of A β [352]. Others emphasize the changes in aggregation behavior of the produced A β variants themselves, as e.g. the highly aggregation-prone Arctic E22G variant[353][354].

As explained above, neither of these two features can explain the pathogenicity of APP variations: The A β_{42} /A β_{40} ratio increases significantly vs. wild type in only two variants, D7H and E11K[9]. Total A β levels increase in A2V, D7H, E11K, K16N, and A21G, all in the N-terminal half. The assumed protective A2T variant reduces A β levels possibly by modifying the β -cleavage site[355], as the Swedish mutant. However, the pathogenic Osaka E22 Δ variant also reduces A β levels, and the English H6R, Tottori D7N, Arctic E22G, Italian E22K, and Dutch E22Q do not change A β levels significantly[9]. If overproduction of A β (despite unaltered ratios) by A2V and the Swedish mutation should cause AD, it would be by a mechanism distinct from most APP and PSEN1 mutations. Yet,

researchers curiously continue to discuss models of AD, such as the Swedish model discussed below, as if overexpression of A β due to altered APP cleavage is a central feature of the disease.

If altered APP cleavage cannot explain the FAD/CAA mutants of APP, then, if we rely on the amyloid hypothesis, the changed product has to be pathogenic in those other cases where A β itself is changed without affecting β -cleavage, i.e. instead of levels (quantitative gain of function) it must be properties (qualitative gain of function). As discussed previously, there is no indication that the aggregation propensities, as presumably related to disease within the gain-of-function paradigm, has anything to do with disease: Many variants do have higher aggregation propensity than the wild type A β , which is rationalized by their tendency to increase hydrophobic exposure or reduced hydrophilicity[118]. However, there is no positive relationship between disease severity and aggregation tendency, in fact perhaps even the opposite: The four clinically most severe variants, A21G and A2V, E22Q, and E22 Δ (age of symptom onset from 36–52 years) have *smaller* tendencies to aggregate than some other variants such as the English and Tottori variants with 56–61 years of onset[9], i.e. aggregation is not pathogenic and perhaps even protective.

Instead, the increased amyloid production seen in cultured mutant cell models resulting from mutation in the N-terminal of A β can be explained as a changes in metal-binding properties, with metal-binding ligand residues such as histidine, aspartate, and glutamate being changed in these mutations[269][356]. The question then emerges whether metal binding is impaired only in the free produced A β , or also in APP prior to APP cleavage, if the same site is accessible in the membrane-bound APP before cleavage. Copper increases APP expression and A β formation *via* CUTA interaction with the β -cleavage site of APP[286]. The N-terminal metal site of A β , which is also the β -cleavage site, constitutes the actual site that regulates β -secretase cleavage of APP[288]. It is notable that Cu(II) and Zn(II) bind differently to A β , and Cu(II) binds more strongly[19][357], so binding of the two metal ions may also have different effects on APP cleavage.

If the metal binding capacity of A β is reduced by direct mutation, as is the case in N-terminal FAD mutants such as D7H[358] but not C-terminal CAA mutants such as A21G[359], it would reduce the peptide's normal function of metal export, to cause the observed cell toxicity. *This mechanism would reconcile FAD-causing N-terminal A β variants with the more common PSEN1 phenotypes that cause depletion of functional A β by reduced catalytic cleavage of APP.* Currently, the amyloid hypothesis does not reconcile these phenotypes, because the APP variants do not have the same general tendency of increasing the A β_{42} /A β_{40} ratio as the PSEN1 mutants do[9]. It explains why the very different phenotypes of APP variants can all cause disease, which has not previously been explained: Notably, N-terminal A β variants that increase amyloid levels have impaired metal binding function, whereas the remaining variants increase aggregation propensity or affect APP cleavage by γ -secretase.

The coupling to presenilin

Any theory of AD pathology must explain not only the A β imbalances but also the important role of PSEN. As discussed above, almost 200 PSEN1 mutations and a smaller amount of PSEN2 mutations cause early-onset FAD; within the gain-of-function amyloid hypothesis, these are thought to be pathogenic by their effect on APP cleavage, which generally leads to an increase of the observed A β_{42} /A β_{40} ratio[97][119]. However, PSEN1's own functions also receive attention[59][60][303], and γ -secretase processes more than 20 other substrates, including Notch[360]. The number of PSEN1 mutations vs. APP mutations and the distinct functions of PSEN1 outside the γ -secretase, among other facts, have inspired a hypothesis that AD is due to PSEN1 loss of function[59]. The most established function of PSEN is its involvement in calcium homeostasis, as summarized by the following observations:

- i) PSEN1 is homologous to calcium transporters and has a ion-channel-like topology[243][361].

Recently, the structure of PSEN1-containing γ -secretase has been elucidated in substantial detail: The

3-dimensional structure of human γ -secretase was determined using single-particle cryo-electron microscopy[153][362], with PSEN having nine transmembrane helices resembling a barrel-like domain protecting the active site where two aspartates cleave APP in the membrane[153][360]. PSEN1 can work within the γ -secretase complex or without it[363][364].

ii) Consistent with these structural features, PSEN1 works as a calcium channel independently of its role in γ -secretase activity[361][347][365]. Although a calcium-leak effect in the endoplasmic reticulum (ER) has been disputed by at least one group[366], the role of PSEN1 in calcium homeostasis of the ER is established[303][367][368]. PSEN1 mutations impair calcium homeostasis and show elevated calcium levels upon exposure to A β [348], and soluble APP α (sAPP α) fragment produced from APP restores calcium homeostasis and rescues PSEN1 mutant-exposed cells from apoptosis[369].

iii) PSEN1-knockout also causes loss of copper and zinc uptake and subsequent deficiency of these metal ions in brains of mice, leading to loss of superoxide dismutase 1 (SOD1) activity [346], the main antioxidant cytosolic copper-zinc protein that is also the main genetic risk factor of familial ALS [370][371].

One of the main processes of cell turnover is the lysosomal degradation of cell parts including aggregated proteins in the cytoplasm by autophagy[372]; this clearance process is necessary for neurons to survive and is impaired in AD[367][373][374][375]. PSEN1 is important for lysosomal protein degradation and autophagy, which is impaired by FAD-causing PSEN1 mutations[376][377]. At the molecular level, PSEN1 helps to fold and glycosylate vacuolar ATPase that is essential for lysosome acidification and thus, activation of autophagy[376]; there is substantial evidence for a link between lysosomal failure in AD and calcium dyshomeostasis caused by PSEN1 dysfunction, as recently reviewed[367].

The role of apolipoproteins in copper/zinc homeostasis

An accurate etiology of AD should also explain the important risk factor associated with the isoform 4 of apolipoprotein E (ApoE4). Relevant to the presented hypothesis, González et al. found that serum levels of zinc, copper, and insulin are significantly higher in ApoE4 allele carriers[378]. Zinc deficiency also reduces expression of apolipoproteins[379], whereas copper deficiency has been found in several studies to increase apolipoprotein levels[380][381]. In transgenic mice carrying the ApoE4 isoform, tau aggregation was modulated by zinc, i.e. zinc and ApoE4 work together to produce tau pathology[382]. These results show, from various points of view, important crosstalk between ApoE proteins and zinc and copper levels.

Also of interest in this context, clusterin (apolipoprotein J) has been shown to be upregulated upon zinc exposure[383]; this observation potentially relates clusterin, a risk factor of AD[69], to zinc-dependent aging regulation. Clusterin has been found to work as a chaperone that regulates the turnover of copper ATPases that are central to brain copper homeostasis[384], as shown in several neurological diseases but perhaps best in Wilson's disease where mutations in these copper proteins directly cause disease[385]. Such mutations have indeed recently been related to ApoE4, as carriers of this isoform show earlier onset of Wilson's disease[386]. A consistent explanation of the various findings summarized above is that the lipoproteins are involved in the metal-transport function of A β .

The Swedish mutation and why mice do not develop AD

Whereas loss of function accounts for the therapeutic window of A β , the PSEN1 phenotypes and adverse outcomes of clinical A β -containment strategies, the gain-of-function amyloid hypothesis seems more consistent with the fact that some AD-causing APP mutations, notably the Swedish K670M/N671L double mutant[387], increase steady-state A β levels multiple times compared to wild type APP[388][389], potentially by enhancing the β -cleavage vs. α -cleavage of APP[352]. The

Swedish mutation was widely heralded as support of the early "quantitative" cascade hypothesis and is still used as a model of AD in mice[390][391].

However, several other AD-related APP mutations produce similar or reduced A β levels vs. wild type and heterogeneous phenotypes, and the A β_{42} /A β_{40} ratio does not generally increase[9][388]. This makes the Swedish mutation phenotype-wise, and in terms of chemical effect on APP cleavage, very distinct from other APP mutations. Furthermore, the curious double-mutation has only ever been identified in a few families, making the genotype extremely rare. The combined rarity of phenotype and genotype renders the widespread use of this mutant as a transgenic mouse model of AD curious considering the amount of both APP and PSEN1 mutant phenotypes that actually lower A β levels. *The Swedish mutation increases total A β levels, but does not change the ratio, whereas most other mutants related to AD do the exact opposite.*

Yet, the Swedish mutant does produce cognitive deficits when overexpressed in mice, how can this be reconciled with the hypomorphic PSEN1 phenotypes? One reasonable answer is that the Swedish mutant causes A β overproduction that causes the adverse effects by depleting intracellular metal status. Yankner et al.[171] already showed that there is a therapeutic window of A β concentrations. In this light, it is curious that no one has considered the possibility that the seemingly contradictory phenotypes of PSEN1 and Swedish mutants could be reconciled by this therapeutic window: In the former case, A β is depleted either by lowered production or increased oligomerization, in the latter case it is over-abundant and potentially aggregating, putting A β levels easily outside the healthy range in both cases. The suggested metal transport function rationalizes the observation of this this window.

Plaque load is substantially reduced if the zinc transporter ZnT3 is knocked out, showing that plaque formation depends on the function of zinc transport[392]. In contrast, ZnT3 knockout by itself gives age-dependent cognitive deficits in mice[308]. Overexpression of this mutant reduces SOD1

activity, a sign of copper deficiency, which could be remedied by copper exposure, showing that the Swedish mutant has a specific adverse effect on copper homeostasis in cells[282]; this effect can explain why the Swedish mutant gives AD in a way consistent with other mutants but unrelated to the high production of A β ; i.e. while the APP cleavage is affected, other properties of the protein that relate to its copper homeostasis are affected too.

Why do cell/mouse FAD models give different results from human patient clinical trials? If the herein stated mechanisms are true, cell toxicity commonly measured upon expression of FAD mutants in cultured neurons and mice is due to extensive A β -metal export during overexpression of APP mutants and PSEN1 mutants. Incidentally, the normal wild-type mouse A β contains three different amino acids within the metal binding N-terminal: R5G, Y10F, and H13R. The host wild type A β is less toxic and less aggregation-prone than human A β and will modulate the amyloid pathology of such models unless it is knocked out[393]. Mouse A β still binds copper but differently from human A β [394]. It has been found that while copper binding and reduction is impaired in mouse A β due to these substitutions, the oxidative stress inducing effects have been found to be similar[395].

According to the arguments presented here, the transgenic mouse models relying on mutant overexpression cause A β production that lead to intra-neuronal metal depletion and impairment of the ability of synapses to maintain Cu/Zn/Ca gradients. In contrast, *in actual humans suffering from FAD, the APP copy number is stable over long periods of time* and lead to *impaired* metal export competence, because both PSEN1 mutants and APP mutants display reduced metal export capacity, and this causes *intra-neuronal metal overload*. This explanation is supported by the observation that zinc overload increases the extend of APP cleavage and extracellular metal-enriched A β deposits[351]; an impaired APP/A β system would be less capable of exporting metals and this would undermine Cu/Zn and Cu/Ca ratios, in particularly at high age when the brain is more exposed to oxidative stress and metal dyshomeostasis, according to quantitative proteomics studies of the aging human brain[38].

These explanations are consistent with the mechanism suggested above, reconcile cell/mouse vs. human data, and link PSEN1 calcium transport function to APP/A β .

Figure 7. APP cleavage and neuronal metal transport: A suggested mechanism of function.

The tau connection

As mentioned, filaments of hyper-phosphorylated tau, i.e. neurofibrillar tangles, constitute a prevailing histopathological feature of AD[23][41]. Normally, the protein associates with the microtubules and maintain cytoskeleton integrity. However, the phosphorylation is related to loss of tau from microtubules and formation of structures that are seen as tangles[396][397]. It is not clear how tau pathology relates to amyloid pathology, although various links have been suggested. However, aggregation of tau is, as most other proteins, triggered by post-translational modifications: As has been

recently shown, zinc-tau interactions fundamentally determine tau phosphorylation and tau toxicity[398], and free zinc induces tau phosphorylation[399] and aggregation[400]. Therefore, tau pathology can be an early feature of metal dyshomeostasis[46][382], and tau hyperphosphorylation and aggregation may increase as cytoskeletons are dismantled during controlled cell death in the stage of neurodegeneration in a deteriorating vicious cycle of increased oxidative stress, metal imbalances, tau and amyloid pathology that reinforce each other[19].

Loss of function is consistent with A β -related biomarkers of disease

Two of the five most commonly used biomarkers of AD relate directly to A β , i.e. the measurement of A β ₄₂ levels in the cerebrospinal fluid, and Positron Emission Tomography (PET) A β imaging[111]. However, the idea that these biomarkers relate to gain of toxic A β is an assumption, and below it is argued that these biomarkers more suitably indicate loss of A β function.

Amyloid deposits build up gradually over many years in AD[401], and positive PET imaging of A β deposits usually accompanies AD diagnosis[18][402]. However, as discussed above, plaque deposits are no longer considered the pathogenic feature of AD, both because many cognitively normal people have such deposits[108][109][110], because deposition does not correlate with cognitive decline[106][107], because aggregation tendencies of A β variants do not correlate with clinical severity[9], and because plaques, which are extracellular insoluble deposits of A β , are not very toxic, whereas intracellular soluble oligomers of A β are[112][113][114][115][116]. In contrast, a high plaque load may in some people indicate protective ability to export pathogenic forms of A β from cells[117][118]. The deposits may still represent pre-clinical disease states[111], and the PET imaging will continue to provide valuable information on amyloid balance, but its relationship to amyloid gain of toxic function etiology is not evident. Instead, since these deposits are not molecularly active inside the neurons, they primarily indicate that neuronal A β balance is disturbed, or more specifically, I argue

that they indicate a *depletion* of functional monomers inside neurons as a result of depositing of A β in plaques.

Similarly, reduced A β_{42} in the cerebrospinal fluid is a useful biomarker of AD that correlates strongly to positive PET imaging discussed above[111]. In early-onset FAD, A β_{42} levels were reduced already 25 years before cognitive symptoms[403]. The inverse correlation between A β_{42} in the cerebrospinal fluid and extracellular insoluble plaque deposits from PET imaging[404] strongly indicates that the soluble pools of A β_{42} have been depleted in favor of the deposits; since the deposits are not pathogenic, depletion of soluble A β_{42} seems consistent with loss of soluble A β from the neurons, i.e. if the overall soluble pool of functional A β has been depleted in favor of non-functional oligomers and aggregates. In contrast, surplus of soluble intracellular A β_{42} oligomers as argued by the more recent versions of the gain-of-function hypothesis is not directly commensurable with this depletion, because as oligomers belong to soluble pools, they would be expected to be in equilibrium with cerebrospinal fluid levels. The temporal ordering of biomarker output[111][405] is thus consistent with a gradual loss of the functional monomer pool, caused by increased demand for the peptide due to neuronal age-dependent stress, including metal dyshomeostasis, and due to the removing of monomers by continuous A β aggregation over time.

Relation to the main clinical outcome, memory loss

How does the suggested APP/A β divalent metal transport system relate to neuronal signaling and memory loss? As has been known for 25 years, AD is particularly characteristic by the loss of *synapses* rather than merely neurons[406][407]. The cholinergic hypothesis has for many years reflected the direct impairment of forebrain pathways of the acetylcholine-rich neurons involved in attention and working memory[49][50] but was challenged by its weaker association with histopathology and genetic

risk factors[408]. The evidence for a physiological function of the APP/A β system in signaling is as follows:

First, APP localizes in the pre- and postsynaptic compartments and is expressed in glutamatergic neurons, and NMDA receptor activation reduces A β production by activation of α -secretases, the zinc peptidases that cleave APP within the A β region to prevent A β production[114][409] (different previous results could be explained by transcriptional regulation upon prolonged NMDA receptor stimulation[409]). NMDA receptor activation is characterized by the channeling of metal ions through the neuron membrane, directly relating A β to this function that is essential for synaptic plasticity and memory[410][411].

Second, synapses are targeted by A β [412] and synaptic structure is affected by A β [413]; this could be a mode of toxicity, as has been suggested[414], but given the peptide's natural functions, *co-location with synapses could equally well be a result of A β 's normal function*. This is supported by findings that A β regulates vesicle release in hippocampal synapses, with extracellular A β proportional to release probability[169]. Again, the concentration range in vesicles becomes critical, as the therapeutic window between neurotropic and toxic features is narrow[171].

These findings are consistent with the function suggested above, i.e. that A β is involved in divalent metal cross-membrane transport during neuronal signaling, as also implied by the findings of Ramsden et al.[276][415]. This function would immediately explain the need for a delicate balance of A β levels, as argued by Pearson and Peers[168], as such a balance parallels the delicate homeostasis of metal ions: Indeed, Abramov et al. found that short-term synaptic facilitation required balanced A β levels, as impairment resulted from both too high and too low levels of A β [169]. Synaptic activity requires the repeated flow of glutamate, calcium, and zinc in order to enable neuron signaling and memory formation [19][28][279][328], providing the rationale for such a function of A β in synapses.

Oxidative stress, proteostasis, metabolism, and mitochondria

Oxidative stress is a general feature of AD; most affected tissue bears signs of massive oxidative stress in the form of oxidized proteins and lipids[48][416]. Oxidations of proteins also affect protein turnover by modifying the surfaces of proteins and subjecting them to proteolysis[417]. The importance of protein turnover in AD and related neurodegenerative diseases is evident not just from the protein misfolding characteristic to these diseases, but also from risk factors relating to protein quality control[129]. It is notable that calcium play a key role in proteostasis regulation, and several regulators of proteostasis work by inhibiting calcium channels to decrease cytoplasmic calcium levels, which upregulate protein quality control machinery[129].

Protein misfolding also plays a main role in ALS, although the pathogenic mechanism of the misfolded proteins remains unclear[418]. However, recently, it was shown that survival times of patients carrying a mutation in SOD1 correlate inversely with the energy cost of turnover of the particular SOD1 mutant[281]. This energy increase is typically caused by loss of stability and increased aggregation due to mutation or post-translational modification, but also depends on protein copy number and specific turnover costs that may play out within the RNA pool[419]. This suggests that neurodegenerative diseases may be caused by neuronal energy deficiency at least partly owing to increased protein turnover; if so, misfolded proteins do not cause disease by some molecular toxic mode, but rather indirectly via their burden on systemically available neuron maintenance energy[281].

AD has been viewed by some as a mitochondrial disease[139][140][141][142][420], and A β can accumulate in mitochondria and interact with inner mitochondrial membranes where neuron energy is produced[139]. As discussed above, the evidence of A β as a small metal-binding[19][31][248] membrane-interacting[135][207] peptide seems strongly supported by its chemical amphiphilic nature and its conformational features[9][213]. A β causes permeabilization of cell membranes by channel formation[133][135][277][278][279]. The resulting calcium dyshomeostasis is massively

documented[29][30][137][242][421]. If APP/A β controls secondary metal ion balances, then its impairment would compromise metal homeostasis. Metal ion dyshomeostasis is a two-edged sword in terms of energy: Loss of functional bound metal pools undermines the proteostatic machinery and prevents refolding of metalloproteins, which increases proteome maintenance costs due to increased protein turnover[281]. In addition, the imbalances in metal pools will most likely increase ion-pump energy costs as well. Protein turnover and ion gradient maintenance are the two main energy requiring processes of cells[419]. The increased demand for neuronal energy will put strain on mitochondria and cause pathological changes, increased ROS production, and plausibly, once the neuron maintenance energy requirements can no longer be met, apoptosis of the neurons in question. These neurons are, incidentally, often the most energy demanding and metal-enriched cells of the hippocampus where AD often initiates.

Thus, it is not surprising that neurons, among the most energy-requiring cells of the body, are particularly sensitive to protein misfolding, oxidative stress and metal dyshomeostasis: In the "energy hypothesis" of neurodegenerative diseases[281], the known metabolic features of these diseases can be coupled to the protein misfolding and explain why these diseases occur specifically in neurons, where allocation of energy to ion pumps is particularly required. Neuronal exhaustion will be endangered by chemical aging, as seen in the upregulation of proteins relating to exactly anti-stress function, calcium-regulation, and fatty acid metabolism in aging human brains[38]. Such pathology would be fueled by metal ion dyshomeostasis caused by ineffective APP/A β /PSEN1 divalent metal transport resulting from FAD-related mutations, both in terms of the increased cost of ion pumping and because metal dyshomeostasis increases misfolding of metalloproteins central to AD[19]; this is possibly the reason why APP and PSEN mutations cause AD in earlier age as the energy threshold that triggers neuron death will be reached earlier.

Thus, SAD and FAD can be unified within the loss of function mechanism. In contrast, within the amyloid hypothesis, it is unclear how SAD arises by accumulation of pathogenic A β oligomers and how aging triggers AD.

Perspectives on diagnosis and treatment of AD

AD needs to be diagnosed as early as possible to enable timely treatment that can prolong lifespan[403]. At the time that patients are diagnosed, disease progression already prevents major improvements in prospects[37][403][422]. As argued previously[19], since this disease represents an imbalance gradually aggravated by aging processes, the only viable biomarkers are abundance *ratios* that quantify relative levels of the chemical species involved in disease progression. Markers of accelerated chemical aging such as e.g. early oxidative stress or lipid metabolism should be combined with markers such as A β_{42} /A β_{40} , Cu/A β_{40} , and Ca/A β_{40} . Also, tissue-specific Cu/Zn and Cu/Ca vs. healthy controls may be relevant markers of the metal dyshomeostasis that is suggested to cause AD.

In addition to the development of effective early biomarkers based on chemical aging and metal homeostasis perturbations, a treatment should address the imbalances described in this review. Given the presented mechanism of disease, it is not particularly surprising that Mediterranean diets and active life styles reduce risk of AD[84][91][92]. Obviously, such risk modifiers should be actively applied in treatment strategies; anything else would be neglect of the available tools to secure optimal patient life quality. While we do not know the active ingredients in all cases, a healthy and varied diet with vegetables, olives, and fish, green tea, coffee and curry is known to reduce AD risk[92][423]. Such a diet should be complemented by effective medicine if possible, which, according to the mechanisms suggested in this review, should have as a strategy to *rebalance* A β levels rather than *deplete* them entirely; the latter strategy has so far failed, as discussed above. Based on the evidence provided here, A β balancing would be a key aspect of a treatment strategy. It could further be combined with anti-

inflammatory hormone treatment and possibly additional zinc and anti-oxidant vitamin supplements. When combined with a carefully monitored treatment strategy pursuing an active cognitive life-style, this would, in this author's opinion, provide the best possible multi-factor treatment strategy of this terrible disease, although much research will clearly be needed to identify the most relevant compounds in such a strategy.

Concluding remarks

In this review, the anomalies and inconsistencies of the current version of the amyloid hypothesis have been addressed in an attempt to provide a fully consistent etiology of AD. This etiology centers on the identification of the normal physiological function (a natural role has already been implied by many lines of research) of the APP/A β system and PSEN all related to maintaining relative metal ion levels within the neuron. These metal balances, notably the Cu/Zn and Cu/Ca ratios, are clearly affected by these proteins as seen from multiple studies. Impairment of the function of these proteins is then argued to be the cause of early-onset familial AD, and this enables a unification, not only of the amyloid, oxidative stress, and metal ion hypothesis of AD, but also of the sporadic and familial forms of disease, as discussed in the latter part of the review.

The loss-of-function etiology of AD provides solutions to inconsistencies that are not currently accounted for by the gain-of-function amyloid hypothesis that dominates the field. It also has substantially more explanatory power while preserving the role of A β aggregation, not as a pathogenic mode of action, but as a loss of the functional A β monomers. The gain-of-function amyloid hypothesis, without a function clarified, provides a link to the genetic risk factors APP and PSEN1 and PSEN2, but not to the main genetic risk factor of SAD, ApoE4, and the main risk factor of AD, age. With a function clarified, all these features can be understood in context. Notably, the amyloid deposits often taken to indicate overload are interpreted instead here as a sign of intracellular functional monomer

deficiency. To prove this theory, the extracellular and intracellular A β pools must be separated into their various types, to test whether A β levels are indeed deficient inside neurons of people with AD. The loss of function hypothesis explains clinical failures of A β reducing drugs and why inhibition or depletion of A β_{40} by either secretase inhibitors or A β antibodies is lethal to cultured neurons[235], and the findings that A β depletion impairs neuronal activity in mice[166]. Thus, new drug strategies should center on balancing and reconstituting functional monomers rather than strict reduction.

The synthesis provided in this review is not intended to be final; nor is it anywhere close to providing a full detail of the biochemical complexity of this major disease. However, it is the hope of the author that the proponents of different theories on the etiology of AD will see this attempt at a synthesis as a welcome bridging between camps and fields; given the complexity of this disease, such bridging is urgently needed, as is the working together of scientists across disciplines, if we are ever to conquer and defeat this terrible form of dementia that affects so many millions of people today.

Conflicts of interest: The author has no conflicts of interest to declare.

References

- [1] World Health Organization, Fact sheet on dementia, 2015. <http://www.who.int/mediacentre/factsheets/fs362/en/>.
- [2] Alzheimer's Disease International, World Alzheimer Report 2015: The Global Impact of Dementia, 2015. <http://www.worldalzreport2015.org/>.
- [3] M. Prince, R. Bryce, E. Albanese, A. Wimo, W. Ribeiro, C.P. Ferri, The global prevalence of dementia: a systematic review and metaanalysis., *Alzheimers. Dement.* 9 (2013) 63–75.e2. doi:10.1016/j.jalz.2012.11.007.
- [4] M. Goedert, M.G. Spillantini, A century of Alzheimer's disease., *Science.* 314 (2006) 777–781. doi:10.1126/science.1132814.
- [5] J. Karlawish, Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease., *Neurology.* 77 (2011) 1487–1493. doi:10.1212/WNL.0b013e318232ac1a.
- [6] P. Sorrentino, A. Iuliano, A. Polverino, F. Jacini, G. Sorrentino, The dark sides of amyloid in Alzheimer's disease pathogenesis, *FEBS Lett.* 588 (2014) 641–652. doi:10.1016/j.febslet.2013.12.038.
- [7] W.I. Rosenblum, Why Alzheimer trials fail: Removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult, *Neurobiol. Aging.* 35 (2014) 969–974. doi:10.1016/j.neurobiolaging.2013.10.085.
- [8] K. Herrup, The case for rejecting the amyloid cascade hypothesis, *Nat Neurosci.* (2015) 794–799. <http://dx.doi.org/10.1038/nn.4017>.
- [9] M.K. Tiwari, K.P. Kepp, β -Amyloid pathogenesis: Chemical properties versus cellular levels, *Alzheimer's Dement.* in press. (2016). doi:10.1016/j.jalz.2015.06.1895.
- [10] B. De Strooper, Lessons from a Failed γ -Secretase Alzheimer Trial, *Cell.* 159 (2014) 721–726. doi:10.1016/j.cell.2014.10.016.
- [11] A.F. Teich, O. Arancio, Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?, *Biochem. J.* 446 (2012) 165–177. doi:10.1042/BJ20120653.
- [12] T.E. Golde, L.S. Schneider, E.H. Koo, Anti-A β therapeutics in alzheimer's disease: The need for a paradigm shift, *Neuron.* 69 (2011) 203–213. doi:10.1016/j.neuron.2011.01.002.
- [13] B. De Strooper, L. Chávez Gutiérrez, Learning by Failing: Ideas and Concepts to Tackle γ -Secretases in Alzheimer's Disease and Beyond, *Annu. Rev. Pharmacol. Toxicol.* 55 (2015) 419–437. doi:10.1146/annurev-pharmtox-010814-124309.
- [14] L. Bäckman, S. Jones, a. K. Berger, E.J. Laukka, B.J. Small, Multiple cognitive deficits during the transition to Alzheimer's disease, *J. Intern. Med.* 256 (2004) 195–204. doi:10.1111/j.1365-2796.2004.01386.x.
- [15] E. Arnáiz, O. Almkvist, Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease, *Acta Neurol. Scand.* 107 (2003) 34–41. doi:10.1034/j.1600-0404.107.s179.7.x.
- [16] S. Karantzoulis, J.E. Galvin, Distinguishing Alzheimer's disease from other major forms of dementia, *Expert Rev. Neurother.* 11 (2011) 1579–1591. doi:10.1586/ern.11.155.

- [17] K. Blennow, M.J. de Leon, H. Zetterberg, Alzheimer's disease, *Lancet*. 368 (2015) 387–403. doi:10.1016/S0140-6736(06)69113-7.
- [18] G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, et al., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, *Alzheimer's Dement.* 7 (2011) 263–269. doi:http://dx.doi.org/10.1016/j.jalz.2011.03.005.
- [19] K.P. Kepp, Bioinorganic chemistry of Alzheimer's disease., *Chem. Rev.* 112 (2012) 5193–5239. doi:10.1021/cr300009x.
- [20] J. Hardy, D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics., *Science* (80-.). 297 (2002) 353–356. doi:10.1126/science.1072994.
- [21] C.L. Masters, D.J. Selkoe, Biochemistry of amyloid β -protein and amyloid deposits in Alzheimer disease., *Cold Spring Harb. Perspect. Med.* 2 (2012) a006262. doi:10.1101/cshperspect.a006262.
- [22] M. Medina, J. Avila, New perspectives on the role of tau in Alzheimer's disease. Implications for therapy, *Biochem. Pharmacol.* 88 (2014) 540–547. doi:10.1016/j.bcp.2014.01.013.
- [23] M. Goedert, M.G. Spillantini, R. Jakes, D. Rutherford, R.A. Crowther, Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease, *Neuron*. 3 (1989) 519–526. doi:http://dx.doi.org/10.1016/0896-6273(89)90210-9.
- [24] G.E. Gibson, H.-M. Huang, Oxidative stress in Alzheimer's disease, *Neurobiol. Aging*. 26 (2005) 575–578. doi:10.1016/j.neurobiolaging.2004.07.017.
- [25] I. Ferrer, Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease, *J. Bioenerg. Biomembr.* 41 (2009) 425–431. doi:10.1007/s10863-009-9243-5.
- [26] S.M. De la Monte, Type 3 diabetes is sporadic Alzheimer's disease: Mini-review, *Eur. Neuropsychopharmacol.* 24 (2014) 1–7. doi:10.1016/j.euroneuro.2014.06.008.
- [27] J.R. Burdo, Q. Chen, N.A. Calcutt, D. Schubert, The pathological interaction between diabetes and presymptomatic Alzheimer's disease, *Neurobiol. Aging*. 30 (2009) 1910–1917. doi:10.1016/j.neurobiolaging.2008.02.010.
- [28] G. Zündorf, G. Reiser, Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection., *Antioxid. Redox Signal.* 14 (2011) 1275–1288. doi:10.1089/ars.2010.3359.
- [29] S. Chakroborty, G.E. Stutzmann, Early calcium dysregulation in Alzheimer's disease: Setting the stage for synaptic dysfunction, *Sci. China Life Sci.* 54 (2011) 752–762. doi:10.1007/s11427-011-4205-7.
- [30] D.H. Small, Dysregulation of calcium homeostasis in Alzheimer's disease, *Neurochem. Res.* 34 (2009) 1824–1829. doi:10.1007/s11064-009-9960-5.
- [31] H. Kozłowski, M. Luczkowski, M. Remelli, D. Valensin, Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases), *Coord. Chem. Rev.*

256 (2012) 2129–2141. doi:10.1016/j.ccr.2012.03.013.

- [32] L. Mascitelli, F. Pezzetta, M.R. Goldstein, Iron, type 2 diabetes mellitus, and Alzheimer's disease, *Cell. Mol. Life Sci.* 66 (2009) 2943. doi:10.1007/s00018-009-0083-6.
- [33] M.A. Greenough, J. Camakaris, A.I. Bush, Metal dyshomeostasis and oxidative stress in Alzheimer's disease., *Neurochem. Int.* 62 (2013) 540–55. doi:10.1016/j.neuint.2012.08.014.
- [34] J.D. Robertson, A.M. Crafford, W.R. Markesbery, M.A. Lovell, Disruption of zinc homeostasis in Alzheimer's disease, *Nucl. Instruments Methods Phys. Res. Sect. B Beam Interact. with Mater. Atoms.* 189 (2002) 454–458. doi:10.1016/S0168-583X(01)01124-7.
- [35] L.E. Scott, C. Orvig, Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease, *Chem. Rev.* 109 (2009) 4885–4910. doi:10.1021/cr9000176.
- [36] P. Zatta, D. Drago, P. Zambenedetti, S. Bolognin, E. Nogara, A. Peruffo, et al., Accumulation of copper and other metal ions, and metallothionein I/II expression in the bovine brain as a function of aging, *J. Chem. Neuroanat.* 36 (2008) 1–5. doi:10.1016/j.jchemneu.2008.02.008.
- [37] C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, E. Jones, Alzheimer's disease., *Lancet.* 377 (2011) 1019–1031. doi:10.1016/S0140-6736(10)61349-9.
- [38] T. Lu, Y. Pan, S.-Y. Kao, C. Li, I. Kohane, J. Chan, et al., Gene regulation and DNA damage in the ageing human brain., *Nature.* 429 (2004) 883–891. doi:10.1038/nature02661.
- [39] M.A. Beydoun, H.A. Beydoun, A.A. Gamaldo, A. Teel, A.B. Zonderman, Y. Wang, Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis, *BMC Public Health.* 14 (2014) 643. doi:10.1186/1471-2458-14-643.
- [40] R. Mayeux, Epidemiology of neurodegeneration, *Annu. Rev. Neurosci.* 26 (2003) 81–104. doi:10.1146/annurev.neuro.26.043002.094919.
- [41] K.S. Kosik, Tau protein and Alzheimer's disease, *Curr. Opin. Cell Biol.* 2 (1990) 101–104. doi:http://dx.doi.org/10.1016/S0955-0674(05)80038-9.
- [42] K.S. Kosik, C.L. Joachim, D.J. Selkoe, Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease., *Proc. Natl. Acad. Sci. U. S. A.* 83 (1986) 4044–4048.
- [43] R.B. Maccioni, G. Farias, I. Morales, L. Navarrete, The revitalized tau hypothesis on Alzheimer's disease., *Arch. Med. Res.* 41 (2010) 226–231. doi:10.1016/j.arcmed.2010.03.007.
- [44] M. Goedert, Tau protein and the neurofibrillary pathology of Alzheimer's disease, *Trends Neurosci.* 16 (1993) 460–465. doi:http://dx.doi.org/10.1016/0166-2236(93)90078-Z.
- [45] A.I. Bush, R.E. Tanzi, Therapeutics for Alzheimer's disease based on the metal hypothesis., *Neurotherapeutics.* 5 (2008) 421–432. doi:10.1016/j.nurt.2008.05.001.
- [46] A.I. Bush, The Metal Theory of Alzheimer's Disease, *Rev. Lit. Arts Am.* 33 (2013) 277–281. doi:10.3233/JAD-2012-129011.
- [47] G. Perry, A.D. Cash, M.A. Smith, Alzheimer Disease and Oxidative Stress, *J. Biomed. Biotechnol.* 2 (2002) 120–123. doi:10.1155/S1110724302203010.
- [48] K. Honda, G. Casadesus, R.B. Petersen, G. Perry, M.A. Smith, Oxidative stress and redox-active iron in Alzheimer's disease, *Ann. N. Y. Acad. Sci.* 1012 (2004) 179–182.

doi:10.1196/annals.1306.015.

- [49] R.T. Bartus, On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis., *Exp. Neurol.* 163 (2000) 495–529. doi:10.1006/exnr.2000.7397.
- [50] P.T. Francis, A.M. Palmer, M. Snape, G.K. Wilcock, The cholinergic hypothesis of Alzheimer's disease: a review of progress, *J. Neurol. Neurosurg. Psychiatry.* 66 (1999) 137–147. doi:10.1136/jnnp.66.2.137.
- [51] A. Goate, M.C. Chartier-Harlin, M. Mullan, J. Brown, F. Crawford, L. Fidani, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease., *Nature.* 349 (1991) 704–706. doi:10.1038/349704a0.
- [52] R. Sherrington, E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, M. Ikeda, et al., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease., *Nature.* 375 (1995) 754–760. doi:10.1038/375754a0.
- [53] E. Levy-Lahad, W. Wasco, P. Poorkaj, D.M. Romano, J. Oshima, W.H. Pettingell, et al., Candidate gene for the chromosome 1 familial Alzheimer's disease locus, *Science* (80-.). 269 (1995) 973–977. doi:10.1126/science.7638622.
- [54] P. Hollingworth, D. Harold, L. Jones, M.J. Owen, J. Williams, Alzheimer's disease genetics: Current knowledge and future challenges, *Int. J. Geriatr. Psychiatry.* 26 (2011) 793–802. doi:10.1002/gps.2628.
- [55] D.C. Ryman, N. Acosta-Baena, P.S. Aisen, T. Bird, A. Danek, N.C. Fox, et al., Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis, *Neurology.* 83 (2014) 253–260. doi:10.1212/WNL.0000000000000596.
- [56] D. Campion, C. Dumanchin, D. Hannequin, B. Dubois, S. Belliard, M. Puel, et al., Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum., *Am. J. Hum. Genet.* 65 (1999) 664–670. doi:10.1086/302553.
- [57] J. Hardy, Alzheimer's disease: The amyloid cascade hypothesis - An update and reappraisal, *J. Alzheimer's Dis.* 9 (2006) 151–153.
- [58] E. Karran, M. Mercken, B. De Strooper, The amyloid cascade hypothesis for Alzheimer ' s disease : an appraisal for the development of therapeutics, *Nat. Rev. Drug Discov.* 10 (2011) 698–712. doi:10.1038/nrd3505.
- [59] J. Shen, R.J. Kelleher, The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism., *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 403–409. doi:10.1073/pnas.0608332104.
- [60] C.A. Saura, S.-Y. Choi, V. Beglopoulos, S. Malkani, D. Zhang, B.S. Shankaranarayana Rao, et al., Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration., *Neuron.* 42 (2004) 23–36.
- [61] E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families., *Science* (80-.). 261 (1993) 921–923. doi:10.1126/science.8346443.
- [62] K.Y. Kim, B.E. Wood, M.I. Wilson, Risk factors for Alzheimer's diseases: An overview for

clinical practitioners, *Consult. Pharm.* 20 (2005) 224–230.

- [63] H. Bickeböllner, D. Campion, a Brice, P. Amouyel, D. Hannequin, O. Didierjean, et al., Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex., *Am. J. Hum. Genet.* 60 (1997) 439–446.
- [64] T. Kanaki, H. Bujo, S. Hirayama, K. Tanaka, H. Yamazaki, K. Seimiya, et al., Developmental regulation of LR11 expression in murine brain., *DNA Cell Biol.* 17 (1998) 647–657.
- [65] C.R. Scherzer, K. Offe, M. Gearing, H.D. Rees, G. Fang, C.J. Heilman, et al., Loss of apolipoprotein E receptor LR11 in Alzheimer disease., *Arch. Neurol.* 61 (2004) 1200–1205. doi:10.1001/archneur.61.8.1200.
- [66] R.-H. Yin, J.-T. Yu, L. Tan, The Role of SORL1 in Alzheimer's Disease., *Mol. Neurobiol.* 51 (2015) 909–918. doi:10.1007/s12035-014-8742-5.
- [67] J.H. Lee, M. Chulikavit, D. Pang, W.B. Zigman, W. Silverman, N. Schupf, Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome., *Neurosci. Lett.* 425 (2007) 105–109. doi:10.1016/j.neulet.2007.08.042.
- [68] E. Rogaeva, Y. Meng, J.H. Lee, Y. Gu, T. Kawarai, F. Zou, et al., The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease., *Nat. Genet.* 39 (2007) 168–177. doi:10.1038/ng1943.
- [69] C. Medway, K. Morgan, Review: The genetics of Alzheimer's disease; putting flesh on the bones, *Neuropathol Appl Neurobiol.* 40 (2014) 97–105. doi:10.1111/nan.12101.
- [70] L. Bertram, R.E. Tanzi, Genome-wide association studies in Alzheimer's disease, *Hum. Mol. Genet.* 18 (2009) R137–R145. doi:10.1093/hmg/ddp406.
- [71] D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M.L. Hamshere, et al., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, *Nat. Genet.* 41 (2009) 1088–1093. http://dx.doi.org/10.1038/ng.440.
- [72] J.-C. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers, M. Hiltunen, et al., Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, *Nat. Genet.* 41 (2009) 1094–1099. http://dx.doi.org/10.1038/ng.439.
- [73] C.M. Karch, A.M. Goate, Alzheimer's disease risk genes and mechanisms of disease pathogenesis., *Biol. Psychiatry.* 77 (2015) 43–51. doi:10.1016/j.biopsych.2014.05.006.
- [74] R.A. Whitmer, E.P. Gunderson, C.P. Quesenberry, J. Zhou, K. Yaffe, Body mass index in midlife and risk of Alzheimer disease and vascular dementia, *Curr. Alzheimer Res. Curr. Alzheimer Res.* 4 (2007) 103–109.
- [75] M. Kivipelto, T. Ngandu, L. Fratiglioni, M. Viitanen, I. Kåreholt, B. Winblad, et al., Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease, *Arch. Neurol.* 62 (2005) 1556–1560. doi:10.1001/archneur.62.10.1556.
- [76] A.-M. Tolppanen, T. Ngandu, I. Kåreholt, T. Laatikainen, M. Rusanen, H. Soininen, et al., Midlife and Late-Life Body Mass Index and Late-Life Dementia: Results from a Prospective Population-Based Cohort, *J. Alzheimers Dis.* 38 (2014) 201–209. doi:10.3233/jad-130698.
- [77] R.A. Whitmer, D.R. Gustafson, E. Barrett-Connor, M.N. Haan, E.P. Gunderson, K. Yaffe,

Central obesity and increased risk of dementia more than three decades later, *Neurol. Neurol.* 71 (2008) 1057–1064.

- [78] C. Reitz, T. den Heijer, C. van Duijn, A. Hofman, M.M.B. Breteler, Relation between smoking and risk of dementia and Alzheimer disease - The Rotterdam Study, *Neurology*. 69 (2007) 998–1005.
- [79] M.M.B. Breteler, F. Cacciatore, P. Abete, N. Ferrara, C. Calabrese, C. Napoli, et al., Alcohol consumption and risk of dementia: The Rotterdam Study, *Br. Med. J.* 359 (2002) 281–286. doi:10.1212/01.wnl.0000271395.29695.9a.
- [80] A. Ruitenberg, J.C. van Swieten, J.C.M. Witteman, K.M. Mehta, C.M. van Duijn, A. Hofman, et al., Alcohol consumption and risk of dementia: the Rotterdam Study, *Lancet*. 359 (2002) 281–286.
- [81] A.B. Graves, C.M. Vanduijn, V. Chandra, L. Fratiglioni, A. Heyman, A.F. Jorm, et al., Alcohol and tobacco consumption as risk-factors for Alzheimer's disease - a collaborative reanalysis of case-control studies, *Int. J. Epidemiol.* 20 (1991).
- [82] G. Vincze, P. Almos, K. Boda, P. Doeme, N. Bodi, G. Szlavik, et al., Risk factors of cognitive decline in residential care in Hungary, *Int. J. Geriatr. Psychiatry*. 22 (2007) 1208–1216. doi:10.1002/gps.1815.
- [83] A. Ott, R.P. Stolk, A. Hofman, F. VanHarskamp, D.E. Grobbee, M.M.B. Breteler, Association of diabetes mellitus and dementia: The Rotterdam study, *Diabetologia*. 39 (1996) 1392–1397.
- [84] M. Massaia, A.P. Di Ceva, M.B.G. Cappa, P. Zannella, D. Persico, E. Ferrario, et al., Risk factors for dementia of Alzheimer's type: A case-control, retrospective evaluation, *Arch. Gerontol. Geriatr.* (2001) 253–259.
- [85] K. Sanmugam, Depression is a Risk Factor for Alzheimer Disease-Review, *Res. J. Pharm. Technol.* 8 (2015) 1056. doi:10.5958/0974-360X.2015.00181.X.
- [86] C. Dufouila, S. Seshadri, G. Chene, Cardiovascular Risk Profile in Women and Dementia, *J. Alzheimers Dis.* 42 (2014). doi:10.3233/jad-141629.
- [87] D.E. Barnes, K. Yaffe, The projected effect of risk factor reduction on Alzheimer's disease prevalence, *Lancet Neurol.* 10 (2015) 819–828. doi:10.1016/S1474-4422(11)70072-2.
- [88] A.-M. Tolppanen, A. Solomon, J. Kulmala, I. Kareholt, T. Ngandu, M. Rusanen, et al., Leisure-time physical activity from mid- to late life, body mass index, and risk of dementia, *Alzheimers Dement.* 11 (2015) 434–443. doi:10.1016/j.jalz.2014.01.008.
- [89] M. Yamada, F. Kasagi, H. Sasaki, N. Masunari, Y. Mimori, G. Suzuki, Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study, *J. Am. Geriatr. Soc.* 51 (2003) 410–414.
- [90] Y. Lee, J.H. Back, J. Kim, S.-H. Kim, D.L. Na, H.-K. Cheong, et al., Systematic review of health behavioral risks and cognitive health in older adults, *Int. Psychogeriatrics*. 22 (2009) 174–187. doi:10.1017/S1041610209991189.
- [91] B. Singh, A.K. Parsaik, M.M. Mielke, P.J. Erwin, D.S. Knopman, R.C. Petersen, et al., Association of Mediterranean diet with mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis, *J. Alzheimer's Dis.* 39 (2014) 271–282. doi:10.3233/JAD-

130830.

- [92] R. Shah, The Role of Nutrition and Diet in Alzheimer Disease: A Systematic Review, *J. Am. Med. Dir. Assoc.* 14 (2013) 398–402. doi:10.1016/j.jamda.2013.01.014.
- [93] S. Lopes da Silva, B. Vellas, S. Elemans, J. Luchsinger, P. Kamphuis, K. Yaffe, et al., Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis., *Alzheimers. Dement.* 10 (2014) 485–502. doi:10.1016/j.jalz.2013.05.1771.
- [94] M.C. Woodward, Prevention of Alzheimer's disease and other dementias, *J. Pharmac.* 33 (2003) 138–143.
- [95] C.L. Masters, D.C. Gajdusek, C.J.J. Gibbs, The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer's disease., *Brain.* 104 (1981) 535–558.
- [96] G.G. Glenner, C.W. Wong, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein., *Biochem. Biophys. Res. Commun.* 120 (1984) 885–890.
- [97] M.S. Wolfe, Processive proteolysis by γ -secretase and the mechanism of Alzheimer's disease, *Biol. Chem.* 393 (2012) 899–905. doi:10.1515/hsz-2012-0140.
- [98] R. Vassar, B.D. Bennett, S. Babu-Khan, S. Kahn, E.A. Mendiaz, P. Denis, et al., Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE., *Science.* 286 (1999) 735–741. doi:10.1126/science.286.5440.735.
- [99] B. De Strooper, P. Saftig, K. Craessaerts, H. Vanderstichele, G. Guhde, W. Annaert, et al., Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein., *Nature.* 391 (1998) 387–390. doi:10.1038/34910.
- [100] M.S. Wolfe, W. Xia, B.L. Ostaszewski, T.S. Diehl, W.T. Kimberly, D.J. Selkoe, Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity., *Nature.* 398 (1999) 513–517. doi:10.1038/19077.
- [101] S. Naruse, G. Thinakaran, J.J. Luo, J.W. Kusiak, T. Tomita, T. Iwatsubo, et al., Effects of PS1 deficiency on membrane protein trafficking in neurons., *Neuron.* 21 (1998) 1213–1221.
- [102] L. Serneels, T. Dejaegere, K. Craessaerts, K. Horré, E. Jorissen, T. Tousseyn, et al., Differential contribution of the three *Aph1* genes to γ -secretase activity in vivo, *Proc. Natl. Acad. Sci. United States Am.* 102 (2005) 1719–1724. doi:10.1073/pnas.0408901102.
- [103] R. Baumeister, U. Leimer, I. Zweckbronner, C. Jakubek, J. Grunberg, C. Haass, Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate *Caenorhabditis elegans* Notch signalling independently of proteolytic processing., *Genes Funct.* 1 (1997) 149–159.
- [104] J.A. Hardy, G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis., *Science* (80-.). 256 (1992) 184–185.
- [105] R.J. Bateman, L.Y. Munsell, J.C. Morris, R. Swarm, K.E. Yarasheski, D.M. Holtzman, Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo., *Nat. Med.* 12 (2006) 856–861. doi:10.1038/nm1438.
- [106] T. Gomez-Isla, R. Hollister, H. West, S. Mui, J.H. Growdon, R.C. Petersen, et al., Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease., *Ann. Neurol.* 41

(1997) 17–24. doi:10.1002/ana.410410106.

- [107] C. Schmitz, B.P.F. Rutten, A. Pielen, S. Schafer, O. Wirths, G. Tremp, et al., Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease., *Am. J. Pathol.* 164 (2004) 1495–1502. doi:10.1016/S0002-9440(10)63235-X.
- [108] H.J. Aizenstein, R.D. Nebes, J.A. Saxton, J.C. Price, C.A. Mathis, N.D. Tsopelas, et al., Frequent amyloid deposition without significant cognitive impairment among the elderly., *Arch. Neurol.* 65 (2008) 1509–1517. doi:10.1001/archneur.65.11.1509.
- [109] F.H. Bouwman, N.S.M. Schoonenboom, N.A. Verwey, E.J. van Elk, A. Kok, M.A. Blankenstein, et al., CSF biomarker levels in early and late onset Alzheimer's disease., *Neurobiol. Aging* 30 (2009) 1895–1901. doi:10.1016/j.neurobiolaging.2008.02.007.
- [110] J.L. Price, D.W.J. McKeel, V.D. Buckles, C.M. Roe, C. Xiong, M. Grundman, et al., Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease., *Neurobiol. Aging* 30 (2009) 1026–1036. doi:10.1016/j.neurobiolaging.2009.04.002.
- [111] C.R.J. Jack, D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, et al., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade., *Lancet. Neurol.* 9 (2010) 119–128. doi:10.1016/S1474-4422(09)70299-6.
- [112] B.A. Yankner, L.R. Dawes, S. Fisher, L. Villa-Komaroff, M.L. Oster-Granite, R.L. Neve, Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease., *Science* 245 (1989) 417–420. doi:10.1126/science.2474201.
- [113] R. Kaye, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, et al., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis., *Science* 300 (2003) 486–489. doi:10.1126/science.1079469.
- [114] S. Lesne, M.T. Koh, L. Kotilinek, R. Kaye, C.G. Glabe, A. Yang, et al., A specific amyloid-beta protein assembly in the brain impairs memory., *Nature* 440 (2006) 352–357. doi:10.1038/nature04533.
- [115] L.W. Hung, G.D. Cicciotosto, E. Giannakis, D.J. Tew, K. Perez, C.L. Masters, et al., Amyloid-beta peptide (A β) neurotoxicity is modulated by the rate of peptide aggregation: A β dimers and trimers correlate with neurotoxicity., *J. Neurosci.* 28 (2008) 11950–11958. doi:10.1523/JNEUROSCI.3916-08.2008.
- [116] F. Panza, V. Frisardi, D. Seripa, B.P. Imbimbo, D. Sancarolo, G. D'Onofrio, et al., Metabolic Syndrome, Mild Cognitive Impairment and Dementia, *Curr. Alzheimer Res. Curr. Alzheimer Res, Curr Alzh R, Curr Alzheimer Res.* 8 (2011) 492–509.
- [117] A. Lorenzo, B.A. Yankner, Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red., *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 12243–12247.
- [118] M.K. Tiwari, K.P. Kepp, Modeling the Aggregation Propensity and Toxicity of Amyloid- β Variants, *J. Alzheimer's Dis.* 47 (2015) 215–229. doi:10.3233/JAD-150046.
- [119] L. Chávez-Gutiérrez, L. Bammens, I. Benilova, A. Vandersteen, M. Benurwar, M. Borgers, et al., The mechanism of γ -Secretase dysfunction in familial Alzheimer disease, *EMBO J.* 31 (2012) 2261–2274. doi:10.1038/emboj.2012.79.
- [120] G. Multhaup, O. Huber, L. Buee, M.-C. Galas, Amyloid Precursor Protein (APP) Metabolites

APP Intracellular Fragment (AICD), A beta 42, and Tau in Nuclear Roles, *J. Biol. Chem.* 290 (2015) 23515–23522. doi:10.1074/jbc.R115.677211.

- [121] A. Jan, O. Gokce, R. Luthi-Carter, H.A. Lashuel, The ratio of monomeric to aggregated forms of A β 40 and A β 42 is an important determinant of amyloid- β aggregation, fibrillogenesis, and toxicity, *J. Biol. Chem.* 283 (2008) 28176–28189. doi:10.1074/jbc.M803159200.
- [122] F. Chiti, C.M. Dobson, Protein misfolding, functional amyloid, and human disease., *Annu. Rev. Biochem.* 75 (2006) 333–366. doi:10.1146/annurev.biochem.75.101304.123901.
- [123] A. Rauk, The chemistry of Alzheimer's disease., *Chem. Soc. Rev.* 38 (2009) 2698–2715. doi:10.1039/b807980n.
- [124] A.K. Somavarapu, K.P. Kepp, Direct Correlation of Cell Toxicity to Conformational Ensembles of Genetic A β Variants., *ACS Chem. Neurosci.* 6 (2015) 1990–1996. doi:10.1021/acschemneuro.5b00238.
- [125] A.R.A. Ladiwala, J. Litt, R.S. Kane, D.S. Aucoin, S.O. Smith, S. Ranjan, et al., Conformational differences between two amyloid beta oligomers of similar size and dissimilar toxicity., *J. Biol. Chem.* 287 (2012) 24765–24773. doi:10.1074/jbc.M111.329763.
- [126] M. Townsend, G.M. Shankar, T. Mehta, D.M. Walsh, D.J. Selkoe, Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers., *J. Physiol.* 572 (2006) 477–492. doi:10.1113/jphysiol.2005.103754.
- [127] D.M. Walsh, D.J. Selkoe, A beta oligomers - a decade of discovery., *J. Neurochem.* 101 (2007) 1172–1184. doi:10.1111/j.1471-4159.2006.04426.x.
- [128] C. Haass, D.J. Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide., *Nat. Rev. Mol. Cell Biol.* 8 (2007) 101–112. doi:10.1038/nrm2101.
- [129] W.E. Balch, R.I. Morimoto, A. Dillin, J.W. Kelly, Adapting proteostasis for disease intervention., *Science.* 319 (2008) 916–9. doi:10.1126/science.1141448.
- [130] J. Götz, A. Eckert, M. Matamalas, L.M. Ittner, X. Liu, Modes of A β toxicity in Alzheimer's disease, *Cell. Mol. Life Sci.* 68 (2011) 3359–3375. doi:10.1007/s00018-011-0750-2.
- [131] D.M. Walsh, I. Klyubin, J. V Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, et al., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo., *Nature.* 416 (2002) 535–539. doi:10.1038/416535a.
- [132] L. Lecanu, J. Greeson, V. Papadopoulos, Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain., *Pharmacology.* 76 (2006) 19–33. doi:10.1159/000088929.
- [133] C.G. Glabe, Common mechanisms of amyloid oligomer pathogenesis in degenerative disease., *Neurobiol. Aging.* 27 (2006) 570–575. doi:10.1016/j.neurobiolaging.2005.04.017.
- [134] M.F.M. Sciacca, S.A. Kotler, J.R. Brender, J. Chen, D.K. Lee, A. Ramamoorthy, Two-step mechanism of membrane disruption by A β through membrane fragmentation and pore formation, *Biophys. J.* 103 (2012) 702–710. doi:10.1016/j.bpj.2012.06.045.
- [135] N. Arispe, E. Rojas, H.B. Pollard, Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum., *Proc. Natl. Acad.*

Sci. U. S. A. 90 (1993) 567–571. doi:10.1073/pnas.90.2.567.

- [136] A. Quist, I. Doudevski, H. Lin, R. Azimova, D. Ng, B. Frangione, et al., Amyloid ion channels: a common structural link for protein-misfolding disease., *Proc. Natl. Acad. Sci. U. S. A.* 102 (2005) 10427–10432. doi:10.1073/pnas.0502066102.
- [137] A. Demuro, I. Parker, G.E. Stutzmann, Calcium signaling and amyloid toxicity in Alzheimer disease, *J. Biol. Chem.* 285 (2010) 12463–12468. doi:10.1074/jbc.R109.080895.
- [138] H. You, S. Tsutsui, S. Hameed, T.J. Kannanayakal, L. Chen, P. Xia, et al., A β neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors, *Proc. Natl. Acad. Sci.* 109 (2012) 1737–1742. doi:10.1073/pnas.1110789109.
- [139] C. Caspersen, N. Wang, J. Yao, A. Sosunov, X. Chen, J.W. Lustbader, et al., Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease., *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 19 (2005) 2040–2041. doi:10.1096/fj.05-3735fje.
- [140] J.W. Lustbader, M. Cirilli, C. Lin, H.W. Xu, K. Takuma, N. Wang, et al., ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease., *Science.* 304 (2004) 448–452. doi:10.1126/science.1091230.
- [141] N. Dragicevic, M. Mamcarz, Y. Zhu, R. Buzzeo, J. Tan, G.W. Arendash, et al., Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice., *J. Alzheimers. Dis.* 20 Suppl 2 (2010) S535–50. doi:10.3233/JAD-2010-100342.
- [142] M. Manczak, T.S. Anekonda, E. Henson, B.S. Park, J. Quinn, P.H. Reddy, Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression., *Hum. Mol. Genet.* 15 (2006) 1437–1449. doi:10.1093/hmg/ddl066.
- [143] S. Vivekanandan, J.R. Brender, S.Y. Lee, A. Ramamoorthy, A partially folded structure of amyloid- β (1-40) in an aqueous environment, *Biochem. Biophys. Res. Commun.* 411 (2011) 312–316. doi:10.1016/j.bbrc.2011.06.133.
- [144] Y. Xiao, B. Ma, D. McElheny, S. Parthasarathy, F. Long, M. Hoshi, et al., Abeta(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease., *Nat. Struct. Mol. Biol.* 22 (2015) 499–505. doi:10.1038/nsmb.2991.
- [145] M.A. Fernandez, J.A. Klutkowski, T. Freret, M.S. Wolfe, Alzheimer Presenilin-1 Mutations Dramatically Reduce Trimming of Long Amyloid β -Peptides (A β) by γ -Secretase to Increase 42-to-40-Residue A β , *J. Biol. Chem.* 289 (2014) 31043–31052. doi:10.1074/jbc.M114.581165.
- [146] M. Cacquevel, L. Aeschbach, J. Houacine, P.C. Fraering, Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ -secretase complexes, *PLoS One.* 7 (2012) 1–13. doi:10.1371/journal.pone.0035133.
- [147] G. Woodruff, J.E. Young, F.J. Martinez, F. Buen, A. Gore, J. Kinaga, et al., The Presenilin-1 δ E9 Mutation Results in Reduced γ -Secretase Activity, but Not Total Loss of PS1 Function, in Isogenic Human Stem Cells, *Cell Rep.* 5 (2013) 974–985. doi:10.1016/j.celrep.2013.10.018.
- [148] M. Bentahir, O. Nyabi, J. Verhamme, A. Tolia, K. Horre, J. Wiltfang, et al., Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms., *J. Neurochem.* 96

(2006) 732–742. doi:10.1111/j.1471-4159.2005.03578.x.

- [149] M. Takami, Y. Nagashima, Y. Sano, S. Ishihara, M. Morishima-Kawashima, S. Funamoto, et al., gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment., *J. Neurosci.* 29 (2009) 13042–13052. doi:10.1523/JNEUROSCI.2362-09.2009.
- [150] A. Fukumori, R. Fluhner, H. Steiner, C. Haass, Three-amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma-secretase-mediated intramembrane proteolysis., *J. Neurosci.* 30 (2010) 7853–7862. doi:10.1523/JNEUROSCI.1443-10.2010.
- [151] C. Haass, C. Kaether, G. Thinakaran, S. Sisodia, Trafficking and proteolytic processing of APP., *Cold Spring Harb. Perspect. Med.* 2 (2012) a006270. doi:10.1101/cshperspect.a006270.
- [152] P. Lu, X. Bai, D. Ma, T. Xie, C. Yan, L. Sun, et al., Three-dimensional structure of human γ -secretase, *Nature*. 512 (2014) 166–170. doi:10.1038/nature13567.
- [153] X. Bai, C. Yan, G. Yang, P. Lu, L. Sun, R. Zhou, et al., An atomic structure of human γ -secretase, *Nature*. 525 (2015) 212–218. doi:10.1038/nature14892.
- [154] R. Kong, S. Chang, W. Xia, S.T.C. Wong, Molecular dynamics simulation study reveals potential substrate entry path into gamma-secretase/presenilin-1., *J. Struct. Biol.* 191 (2015) 120–129. doi:10.1016/j.jsb.2015.07.001.
- [155] A.K. Somavarapu, K.P. Kepp, The dynamic mechanism of presenilin-1 function: Sensitive gate dynamics and loop unplugging control protein access., *Neurobiol. Dis.* 89 (2016) 147–156. doi:10.1016/j.nbd.2016.02.008.
- [156] A.K. Somavarapu, K.P. Kepp, Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's Disease., *J. Neurochem.* (2016). doi:10.1111/jnc.13535.
- [157] M.D. Carter, G.A. Simms, D.F. Weaver, The development of new therapeutics for Alzheimer's disease., *Clin. Pharmacol. Ther.* 88 (2010) 475–486. doi:10.1038/clpt.2010.165.
- [158] J.-S. Choi, J.J. Braymer, R.P.R. Nanga, A. Ramamoorthy, M.H. Lim, Design of small molecules that target metal-A β species and regulate metal-induced A β aggregation and neurotoxicity., *Proc. Natl. Acad. Sci. U. S. A.* 107 (2010) 21990–21995. doi:10.1073/pnas.1006091107.
- [159] A.S. DeToma, S. Salamekh, A. Ramamoorthy, M.H. Lim, Misfolded proteins in Alzheimer's disease and type II diabetes, *Chem. Soc. Rev.* 41 (2012) 608. doi:10.1039/c1cs15112f.
- [160] A. Ramamoorthy, M.H. Lim, Structural characterization and inhibition of toxic amyloid- β oligomeric intermediates, *Biophys. J.* 105 (2013) 287–288. doi:10.1016/j.bpj.2013.05.004.
- [161] B.P. Imbimbo, G.A.M. Giardina, gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes., *Curr. Top. Med. Chem.* 11 (2011) 1555–1570.
- [162] J. Nunan, D.H. Small, Regulation of APP cleavage by alpha-, beta- and gamma-secretases., *FEBS Lett.* 483 (2000) 6–10.
- [163] E. Karran, J. Hardy, A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease, *Ann. Neurol.* (2014) 185–205. doi:10.1002/ana.24188.

- [164] K.G. Mawuenyega, W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, J.C. Morris, et al., Decreased clearance of CNS beta-amyloid in Alzheimer's disease., *Science*. 330 (2010) 1774. doi:10.1126/science.1197623.
- [165] K. Pauwels, T.L. Williams, K.L. Morris, W. Jonckheere, A. Vandersteen, G. Kelly, et al., Structural basis for increased toxicity of pathological abeta42:abeta40 ratios in Alzheimer disease., *J. Biol. Chem.* 287 (2012) 5650–5660. doi:10.1074/jbc.M111.264473.
- [166] J.E. Morley, S.A. Farr, W.A. Banks, S.N. Johnson, K.A. Yamada, L. Xu, A physiological role for amyloid- β protein: Enhancement of learning and memory, *J. Alzheimer's Dis.* 19 (2010) 441–449. doi:10.3233/JAD-2010-1230.
- [167] K. Zou, J.-S. Gong, K. Yanagisawa, M. Michikawa, A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage., *J. Neurosci.* 22 (2002) 4833–4841. doi:22/12/4833 [pii].
- [168] H.A. Pearson, C. Peers, Physiological roles for amyloid beta peptides., *J. Physiol.* 575 (2006) 5–10. doi:10.1113/jphysiol.2006.111203.
- [169] E. Abramov, I. Dolev, H. Fogel, G.D. Ciccotosto, E. Ruff, I. Slutsky, Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses., *Nat. Neurosci.* 12 (2009) 1567–1576. doi:10.1038/nn.2433.
- [170] X. Cao, T.C. Sudhof, Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation., *J. Biol. Chem.* 279 (2004) 24601–24611. doi:10.1074/jbc.M402248200.
- [171] B.A. Yankner, L.K. Duffy, D.A. Kirschner, Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides., *Science*. 250 (1990) 279–282.
- [172] W. Qiang, W.-M. Yau, Y. Luo, M.P. Mattson, R. Tycko, Antiparallel beta-sheet architecture in Iowa-mutant beta-amyloid fibrils., *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 4443–4448. doi:10.1073/pnas.1111305109.
- [173] A. Lomakin, D.B. Teplow, D.A. Kirschner, G.B. Benedek, Kinetic theory of fibrillogenesis of amyloid beta-protein., *Proc. Natl. Acad. Sci. U. S. A.* 94 (1997) 7942–7947.
- [174] P. Seubert, C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, et al., Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids., *Nature*. 359 (1992) 325–327. doi:10.1038/359325a0.
- [175] D. Galasko, L. Chang, R. Motter, C.M. Clark, J. Kaye, D. Knopman, et al., High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype., *Arch. Neurol.* 55 (1998) 937–945.
- [176] M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, et al., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins., *Proc. Natl. Acad. Sci. U. S. A.* 95 (1998) 6448–6453. doi:10.1073/pnas.95.11.6448.
- [177] D. Eisenberg, M. Jucker, The amyloid state of proteins in human diseases, *Cell*. 148 (2012) 1188–1203. doi:10.1016/j.cell.2012.02.022.
- [178] T. Jonsson, J.K. Atwal, S. Steinberg, J. Snaedal, P. V Jonsson, S. Bjornsson, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline, *Nature*. 488 (2012) 96–99. doi:10.1038/nature11283.

- [179] I. Benilova, R. Gallardo, A.-A. Ungureanu, V. Castillo Cano, A. Snellinx, M. Ramakers, et al., The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid- β (A β) aggregation., *J. Biol. Chem.* 289 (2014) 30977–30989. doi:10.1074/jbc.M114.599027.
- [180] G.P. Morris, I.A. Clark, B. Vissel, Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease., *Acta Neuropathol. Commun.* 2 (2014) 135. doi:10.1186/s40478-014-0135-5.
- [181] D.R. Howlett, J.C. Richardson, The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP?, *Histol. Histopathol.* 24 (2009) 83–100.
- [182] D. Puzzo, W. Gulisano, A. Palmeri, O. Arancio, Rodent models for Alzheimer's disease drug discovery., *Expert Opin. Drug Discov.* 10 (2015) 703–711. doi:10.1517/17460441.2015.1041913.
- [183] A. V Savonenko, G.M. Xu, D.L. Price, D.R. Borchelt, A.L. Markowska, Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE., *Neurobiol. Dis.* 12 (2003) 194–211.
- [184] H.M. Luo, F. Xiao, Alzheimer-like pathological changes of mice induced by D-galactose and aluminum trichloride, *Chinese J. Pharmacol. Toxicol.* 中国药理学与毒理学杂志, 中國藥理學與毒理學雜誌, *Chin. J. Pharmacol. Toxicol.*, *Zhongguo Yaolixue Yu Dulixue Zazhi*, *Chinese J. Pharmacol. Toxicol.* 18 (2004) 22–26.
- [185] B. De Strooper, Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease., *EMBO Rep.* 8 (2007) 141–146. doi:10.1038/sj.embor.7400897.
- [186] J. Shioi, A. Georgakopoulos, P. Mehta, Z. Kouchi, C.M. Litterst, L. Baki, et al., FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta., *J. Neurochem.* 101 (2007) 674–681. doi:10.1111/j.1471-4159.2006.04391.x.
- [187] X. Zhu, A.K. Raina, G. Perry, M.A. Smith, Alzheimer's disease: the two-hit hypothesis., *Lancet. Neurol.* 3 (2004) 219–226. doi:10.1016/S1474-4422(04)00707-0.
- [188] D.A. Drachman, The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease, *Alzheimer's Dement.* 10 (2014) 372–380. doi:10.1016/j.jalz.2013.11.003.
- [189] A. Tiiman, P. Palumaa, V. Tougu, The missing link in the amyloid cascade of Alzheimer's disease - Metal ions, *Neurochem. Int.* 62 (2013) 367–378. doi:10.1016/j.neuint.2013.01.023.
- [190] D. Boche, J. Donald, S. Love, S. Harris, J.W. Neal, C. Holmes, et al., Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease., *Acta Neuropathol.* 120 (2010) 13–20. doi:10.1007/s00401-010-0705-y.
- [191] R.S. Doody, R.G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, et al., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., *N. Engl. J. Med.* 370 (2014) 311–321. doi:10.1056/NEJMoa1312889.
- [192] H.O. Tayeb, E.D. Murray, B.H. Price, F.I. Tarazi, Bapineuzumab and solanezumab for

- Alzheimer's disease: is the "amyloid cascade hypothesis" still alive?, *Expert Opin. Biol. Ther.* 13 (2013) 1075–1084. doi:10.1517/14712598.2013.789856.
- [193] E.R. Siemers, K.L. Sundell, C. Carlson, M. Case, G. Sethuraman, H. Liu-Seifert, et al., Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients, *Alzheimer's Dement.* 12 (2016) 110–120. doi:http://dx.doi.org/10.1016/j.jalz.2015.06.1893.
- [194] S. Salloway, R. Sperling, N.C. Fox, K. Blennow, W. Klunk, M. Raskind, et al., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease., *N. Engl. J. Med.* 370 (2014) 322–333. doi:10.1056/NEJMoA1304839.
- [195] R.J. Castellani, G. Perry, Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress., *Arch. Med. Res.* 43 (2012) 694–698. doi:10.1016/j.arcmed.2012.09.009.
- [196] K. Blennow, H. Zetterberg, J.O. Rinne, S. Salloway, J. Wei, R. Black, et al., Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease., *Arch. Neurol.* 69 (2012) 1002–1010. doi:10.1001/archneurol.2012.90.
- [197] J.P. Fuller, J.B. Stavenhagen, S. Christensen, F. Kartberg, M.J. Glennie, J.L. Teeling, Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies., *Acta Neuropathol.* 130 (2015) 699–711. doi:10.1007/s00401-015-1484-2.
- [198] R.S. Doody, R. Raman, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, et al., A phase 3 trial of semagacestat for treatment of Alzheimer's disease., *N. Engl. J. Med.* 369 (2013) 341–50. doi:10.1056/NEJMoA1210951.
- [199] V. Coric, C.H. van Dyck, S. Salloway, N. Andreasen, M. Brody, R.W. Richter, et al., Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease., *Arch. Neurol.* 69 (2012) 1430–1440. doi:10.1001/archneurol.2012.2194.
- [200] D.M. Walsh, E. Thulin, A.M. Minogue, N. Gustavsson, E. Pang, D.B. Teplow, et al., A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide., *FEBS J.* 276 (2009) 1266–1281. doi:10.1111/j.1742-4658.2008.06862.x.
- [201] W.B. Stine, L. Jungbauer, C. Yu, M.J. LaDu, Preparing synthetic Abeta in different aggregation states., *Methods Mol. Biol.* 670 (2011) 13–32. doi:10.1007/978-1-60761-744-0_2.
- [202] D.A. Ryan, W.C. Narrow, H.J. Federoff, W.J. Bowers, An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies., *J. Neurosci. Methods.* 190 (2010) 171–179. doi:10.1016/j.jneumeth.2010.05.001.
- [203] A.K. Somavarapu, K.P. Kepp, The Dependence of Amyloid-beta Dynamics on Protein Force Fields and Water Models., *Chemphyschem.* 16 (2015) 3278–3289. doi:10.1002/cphc.201500415.
- [204] A. Deshpande, E. Mina, C. Glabe, J. Busciglio, Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons., *J. Neurosci.* 26 (2006) 6011–6018. doi:10.1523/JNEUROSCI.1189-06.2006.
- [205] I.W. Hamley, The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization., *Chem. Rev.* 112 (2012) 5147–5192. doi:10.1021/cr3000994.

- [206] S.K. Rhee, A.P. Quist, R. Lal, Amyloid beta protein-(1-42) forms calcium-permeable, Zn²⁺-sensitive channel., *J. Biol. Chem.* 273 (1998) 13379–13382.
- [207] N. Arispe, H.B. Pollard, E. Rojas, Zn²⁺ interaction with Alzheimer amyloid beta protein calcium channels, *Proc. Natl. Acad. Sci.* 93 (1996) 1710–1715.
<http://www.pnas.org/content/93/4/1710.abstract>.
- [208] O. Crescenzi, S. Tomaselli, R. Guerrini, S. Salvadori, A.M. D’Ursi, P.A. Temussi, et al., Solution structure of the Alzheimer amyloid β -peptide (1-42) in an apolar microenvironment: Similarity with a virus fusion domain, *Eur. J. Biochem.* 269 (2002) 5642–5648.
doi:10.1046/j.1432-1033.2002.03271.x.
- [209] S. Tomaselli, V. Esposito, P. Vangone, N.A.J. Van Nuland, A.M.J.J. Bonvin, R. Guerrini, et al., The α -to- β conformational transition of Alzheimer’s A β -(1-42) peptide in aqueous media is reversible: A step by step conformational analysis suggests the location of β conformation seeding, *ChemBioChem.* 7 (2006) 257–267. doi:10.1002/cbic.200500223.
- [210] D.J. Rosenman, C.R. Connors, W. Chen, C. Wang, A.E. García, A β monomers transiently sample oligomer and fibril-like configurations: Ensemble characterization using a combined MD/NMR approach, *J. Mol. Biol.* 425 (2013) 3338–3359. doi:10.1016/j.jmb.2013.06.021.
- [211] M. Coles, W. Bicknell, A.A. Watson, D.P. Fairlie, D.J. Craik, Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment., *Biochemistry.* 37 (1998) 11064–77.
doi:10.1021/bi972979f.
- [212] H. Sticht, P. Bayer, D. Willbold, S. Dames, C. Hilbich, K. Beyreuther, et al., Structure of amyloid A4-(1-40)-peptide of Alzheimer’s disease., *Eur. J. Biochem.* 233 (1995) 293–298.
- [213] M.K. Tiwari, K.P. Kepp, Pathogenic properties of Alzheimer’s β -amyloid identified from structure–property patient-phenotype correlations, *Dalt. Trans.* 44 (2015) 2747–2754.
doi:10.1039/C4DT03122A.
- [214] M. Kawahara, N. Arispe, Y. Kuroda, E. Rojas, Alzheimer’s disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons., *Biophys. J.* 73 (1997) 67–75. doi:10.1016/S0006-3495(97)78048-2.
- [215] A.I. Bush, W.H. Pettingell, G. Multhaup, M. d Paradis, J.P. Vonsattel, J.F. Gusella, et al., Rapid induction of Alzheimer A beta amyloid formation by zinc., *Science.* 265 (1994) 1464–1467.
- [216] Y.H. Hung, A.I. Bush, R.A. Cherny, Copper in the brain and Alzheimer’s disease, *J. Biol. Inorg. Chem.* 15 (2010) 61–76. doi:10.1007/s00775-009-0600-y.
- [217] T. Miura, K. Suzuki, N. Kohata, H. Takeuchi, Metal binding modes of Alzheimer’s amyloid beta-peptide in insoluble aggregates and soluble complexes., *Biochemistry.* 39 (2000) 7024–7031.
- [218] D. Drago, S. Bolognin, P. Zatta, Role of metal ions in the A β oligomerization in Alzheimer’s disease and in other neurological disorders, *Curr. Alzheimer Res.* 5 (2008) 500–507.
doi:10.2174/156720508786898479.
- [219] A.K. Sharma, S.T. Pavlova, J. Kim, J. Kim, L.M. Mirica, The effect of Cu(2+) and Zn(2+) on the A β 42 peptide aggregation and cellular toxicity., *Metallomics.* 5 (2013) 1529–36.
doi:10.1039/c3mt00161j.

- [220] K. Murakami, K. Irie, A. Morimoto, H. Ohigashi, M. Shindo, M. Nagao, et al., Neurotoxicity and physicochemical properties of A β mutant peptides from cerebral amyloid angiopathy: Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease, *J. Biol. Chem.* 278 (2003) 46179–46187. doi:10.1074/jbc.M301874200.
- [221] Y. Hori, T. Hashimoto, Y. Wakutani, K. Urakami, K. Nakashima, M.M. Condron, et al., The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate A β fibril formation without increasing protofibril formation, *J. Biol. Chem.* 282 (2007) 4916–4923. doi:10.1074/jbc.M608220200.
- [222] A. Abelein, B. Bolognesi, C.M. Dobson, A. Graslund, C. Lendel, Hydrophobicity and conformational change as mechanistic determinants for nonspecific modulators of amyloid beta self-assembly., *Biochemistry.* 51 (2012) 126–137. doi:10.1021/bi201745g.
- [223] K. Ono, M.M. Condron, D.B. Teplow, Structure-neurotoxicity relationships of amyloid beta-protein oligomers., *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) 14745–14750. doi:10.1073/pnas.0905127106.
- [224] M.A. Lovell, J.D. Robertson, W.J. Teesdale, J.L. Campbell, W.R. Markesbery, Copper, iron and zinc in Alzheimer's disease senile plaques., *J. Neurol. Sci.* 158 (1998) 47–52.
- [225] B. Midthune, S.-H. Tyan, J.J. Walsh, F. Sarsoza, S. Eggert, P.R. Hof, et al., Deletion of the amyloid precursor-like protein 2 (APLP2) does not affect hippocampal neuron morphology or function., *Mol. Cell. Neurosci.* 49 (2012) 448–455. doi:10.1016/j.mcn.2012.02.001.
- [226] S. Heber, J. Herms, V. Gajic, J. Hainfellner, A. Aguzzi, T. Rulicke, et al., Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members., *J. Neurosci.* 20 (2000) 7951–7963.
- [227] M. Korte, U. Herrmann, X. Zhang, A. Draguhn, The role of APP and APLP for synaptic transmission, plasticity, and network function: lessons from genetic mouse models., *Exp. Brain Res.* 217 (2012) 435–440. doi:10.1007/s00221-011-2894-6.
- [228] C.S. von Koch, H. Zheng, H. Chen, M. Trumbauer, G. Thinakaran, L.H. van der Ploeg, et al., Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice., *Neurobiol. Aging.* 18 (1997) 661–669.
- [229] B.A. Bergmans, S.A.M. Shariati, R.L.P. Habets, P. Verstreken, L. Schoonjans, U. Muller, et al., Neurons generated from APP/APLP1/APLP2 triple knockout embryonic stem cells behave normally in vitro and in vivo: lack of evidence for a cell autonomous role of the amyloid precursor protein in neuronal differentiation., *Stem Cells.* 28 (2010) 399–406. doi:10.1002/stem.296.
- [230] X. Zhang, U. Herrmann, S.W. Weyer, M. Both, U.C. Muller, M. Korte, et al., Hippocampal network oscillations in APP/APLP2-deficient mice., *PLoS One.* 8 (2013) e61198. doi:10.1371/journal.pone.0061198.
- [231] S.W. Weyer, M. Klevanski, A. Delekate, V. Voikar, D. Aydin, M. Hick, et al., APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP., *EMBO J.* 30 (2011) 2266–2280. doi:10.1038/emboj.2011.119.
- [232] J.P. Steinbach, U. Muller, M. Leist, Z.W. Li, P. Nicotera, A. Aguzzi, Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice., *Cell Death Differ.* 5 (1998) 858–866.

doi:10.1038/sj.cdd.4400391.

- [233] G.R. Dawson, G.R. Seabrook, H. Zheng, D.W. Smith, S. Graham, G. O'Dowd, et al., Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein., *Neuroscience*. 90 (1999) 1–13.
- [234] M.L. Giuffrida, F. Caraci, B. Pignataro, S. Cataldo, P. De Bona, V. Bruno, et al., β -Amyloid Monomers Are Neuroprotective, *J. Neurosci*. 29 (2009) 10582–10587. doi:10.1523/JNEUROSCI.1736-09.2009.
- [235] L.D. Plant, J.P. Boyle, I.F. Smith, C. Peers, H.A. Pearson, The production of amyloid beta peptide is a critical requirement for the viability of central neurons., *J. Neurosci*. 23 (2003) 5531–5535.
- [236] The amyloid cascade hypothesis has misled the pharmaceutical industry., *Biochem. Soc. Trans.* 39 (2011) 920–923. doi:10.1042/BST0390920.
- [237] S. Zirah, S.A. Kozin, A.K. Mazur, A. Blond, M. Cheminant, I. Segalas-Milazzo, et al., Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging., *J. Biol. Chem.* 281 (2006) 2151–2161. doi:10.1074/jbc.M504454200.
- [238] S.O. Dahms, I. Konnig, D. Roeser, K.-H. Guhrs, M.C. Mayer, D. Kaden, et al., Metal binding dictates conformation and function of the amyloid precursor protein (APP) E2 domain., *J. Mol. Biol.* 416 (2012) 438–452. doi:10.1016/j.jmb.2011.12.057.
- [239] W. Yu, L. Tong, S.H. Kim, M.K.C. Wong, L. Chen, D.-Y. Yang, et al., Biaryl substituted hydantoin compounds as TACE inhibitors., *Bioorg. Med. Chem. Lett.* 20 (2010) 5286–5289. doi:10.1016/j.bmcl.2010.06.134.
- [240] Q. Guo, M. Manolopoulou, Y. Bian, A.B. Schilling, W.-J. Tang, Molecular basis for the recognition and cleavages of IGF-II, TGF- α , and amylin by human insulin-degrading enzyme., *J. Mol. Biol.* 395 (2010) 430–443. doi:10.1016/j.jmb.2009.10.072.
- [241] Z.S. Khachaturian, Hypothesis on the regulation of cytosol calcium concentration and the aging brain., *Neurobiol. Aging*. 8 (1987) 345–346.
- [242] M. Kawahara, M. Negishi-Kato, Y. Sadakane, Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein, *Expert Rev. Neurother.* 9 (2009) 681–693. doi:10.1586/ern.09.28.
- [243] K.N. Green, F.M. LaFerla, Linking calcium to Abeta and Alzheimer's disease., *Neuron*. 59 (2008) 190–194. doi:10.1016/j.neuron.2008.07.013.
- [244] D. Kaden, L.M. Munter, B. Reif, G. Multhaup, The amyloid precursor protein and its homologues: structural and functional aspects of native and pathogenic oligomerization., *Eur. J. Cell Biol.* 91 (2012) 234–239. doi:10.1016/j.ejcb.2011.01.017.
- [245] G. Multhaup, T. Ruppert, A. Schlicksupp, L. Hesse, E. Bill, R. Pipkorn, et al., Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide, *Biochemistry*. 37 (1998) 7224–7230. doi:10.1021/bi980022m.
- [246] L. Hesse, D. Beher, C.L. Masters, G. Multhaup, The beta A4 amyloid precursor protein binding to copper., *FEBS Lett.* 349 (1994) 109–116.
- [247] S.O. Dahms, S. Hoefgen, D. Roeser, B. Schlott, K.-H. Guhrs, M.E. Than, Structure and

- biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein., *Proc. Natl. Acad. Sci. U. S. A.* 107 (2010) 5381–5386. doi:10.1073/pnas.0911326107.
- [248] V. Tōugu, P. Palumaa, Coordination of zinc ions to the key proteins of neurodegenerative diseases: A β , APP, α -synuclein and PrP, *Coord. Chem. Rev.* 256 (2012) 2219–2224. doi:10.1016/j.ccr.2011.12.008.
- [249] K.J. Barnham, W.J. McKinstry, G. Multhaup, D. Galatis, C.J. Morton, C.C. Curtain, et al., Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis, *J. Biol. Chem.* 278 (2003) 17401–17407. doi:10.1074/jbc.M300629200.
- [250] G.K.-W. Kong, J.J. Adams, R. Cappai, M.W. Parker, Structure of Alzheimer's disease amyloid precursor protein copper-binding domain at atomic resolution., *Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun.* 63 (2007) 819–824. doi:10.1107/S1744309107041139.
- [251] G.K.W. Kong, J.J. Adams, H.H. Harris, J.F. Boas, C.C. Curtain, D. Galatis, et al., Structural Studies of the Alzheimer's Amyloid Precursor Protein Copper-binding Domain Reveal How it Binds Copper Ions, *J. Mol. Biol.* 367 (2007) 148–161. doi:10.1016/j.jmb.2006.12.041.
- [252] A.I. Bush, G. Multhaup, R.D. Moir, T.G. Williamson, D.H. Small, B. Rumble, et al., A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease., *J. Biol. Chem.* 268 (1993) 16109–16112.
- [253] M.C. Mayer, D. Kaden, L. Schauenburg, M.A. Hancock, P. Voigt, D. Roeser, et al., Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization., *J. Biol. Chem.* 289 (2014) 19019–19030. doi:10.1074/jbc.M114.570382.
- [254] G. Multhaup, A. Schlicksupp, L. Hesse, D. Beher, T. Ruppert, C.L. Masters, et al., The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I), *Science*. 271 (1996) 1406–1409.
- [255] C.E. Ooi, E. Rabinovich, A. Dancis, J.S. Bonifacino, R.D. Klausner, Copper-dependent degradation of the *Saccharomyces cerevisiae* plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis., *EMBO J.* 15 (1996) 3515–3523.
- [256] A.R. White, G. Multhaup, F. Maher, S. Bellingham, J. Camakaris, H. Zheng, et al., The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures, *J.* 19 (1999) 9170–9179. <http://www.jneurosci.org/content/19/21/9170.short>.
- [257] C.J. Maynard, R. Cappai, I. Volitakis, R.A. Cherny, A.R. White, K. Beyreuther, et al., Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron., *J. Biol. Chem.* 277 (2002) 44670–44676. doi:10.1074/jbc.M204379200.
- [258] C. Treiber, A. Simons, M. Strauss, M. Hafner, R. Cappai, T.A. Bayer, et al., Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease., *J. Biol. Chem.* 279 (2004) 51958–51964. doi:10.1074/jbc.M407410200.
- [259] W.F. Cerpa, M.I. Barria, M.A. Chacon, M. Suazo, M. Gonzalez, C. Opazo, et al., The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu²⁺ neurotoxicity in vivo., *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 18 (2004) 1701–1703. doi:10.1096/fj.03-1349fje.

- [260] I. Singh, A.P. Sagare, M. Coma, D. Perlmutter, R. Gelein, R.D. Bell, et al., Low levels of copper disrupt brain amyloid-beta homeostasis by altering its production and clearance., *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 14771–14776. doi:10.1073/pnas.1302212110.
- [261] T. Kanekiyo, C.-C. Liu, M. Shinohara, J. Li, G. Bu, LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-beta., *J. Neurosci.* 32 (2012) 16458–16465. doi:10.1523/JNEUROSCI.3987-12.2012.
- [262] G. Bu, J. Cam, C. Zerbinatti, LRP in amyloid-beta production and metabolism., *Ann. N. Y. Acad. Sci.* 1086 (2006) 35–53. doi:10.1196/annals.1377.005.
- [263] J.A. Cam, C. V Zerbinatti, J.M. Knisely, S. Hecimovic, Y. Li, G. Bu, The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production., *J. Biol. Chem.* 279 (2004) 29639–29646. doi:10.1074/jbc.M313893200.
- [264] J.D. Buxbaum, A.A. Ruefli, C.A. Parker, A.M. Cypess, P. Greengard, Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner., *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 4489–4493.
- [265] M.P. Mattson, B. Cheng, A.R. Culwell, F.S. Esch, I. Lieberburg, R.E. Rydel, Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein., *Neuron.* 10 (1993) 243–254.
- [266] H.S. Kim, C.H. Park, S.H. Cha, J.H. Lee, S. Lee, Y. Kim, et al., Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity., *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 14 (2000) 1508–1517.
- [267] J.P. Lee, K.A. Chang, H.S. Kim, S.S. Kim, S.J. Jeong, Y.H. Suh, APP carboxyl-terminal fragment without or with abeta domain equally induces cytotoxicity in differentiated PC12 cells and cortical neurons., *J. Neurosci. Res.* 60 (2000) 565–570.
- [268] B.X. Wong, A. Tsatsanis, L.Q. Lim, P.A. Adlard, A.I. Bush, J.A. Duce, beta-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin., *PLoS One.* 9 (2014) e114174. doi:10.1371/journal.pone.0114174.
- [269] P. Faller, C. Hureau, Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide., *Dalton Trans.* (2009) 1080–1094. doi:10.1039/b813398k.
- [270] P. Faller, C. Hureau, G. La Penna, Metal ions and intrinsically disordered proteins and peptides: from Cu/Zn amyloid-beta to general principles., *Acc. Chem. Res.* 47 (2014) 2252–2259. doi:10.1021/ar400293h.
- [271] V. Töugu, A. Karafin, P. Palumaa, Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid- β peptide, *J. Neurochem.* 104 (2008) 1249–1259. doi:10.1111/j.1471-4159.2007.05061.x.
- [272] C.S. Atwood, R.C. Scarpa, X. Huang, R.D. Moir, W.D. Jones, D.P. Fairlie, et al., Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42., *J. Neurochem.* 75 (2000) 1219–1233.
- [273] C.J. Sarell, C.D. Syme, S.E.J. Rigby, J.H. Viles, Copper(II) binding to amyloid-beta fibrils of Alzheimer's disease reveals a picomolar affinity: stoichiometry and coordination geometry are

independent of Abeta oligomeric form., *Biochemistry*. 48 (2009) 4388–4402.
doi:10.1021/bi900254n.

- [274] V. Tōugu, A. Karafin, K. Zovo, R.S. Chung, C. Howells, A.K. West, et al., Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid- β (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators, *J. Neurochem.* 110 (2009) 1784–1795. doi:10.1111/j.1471-4159.2009.06269.x.
- [275] J.I. Kourie, C.L. Henry, P. Farrelly, Diversity of amyloid beta protein fragment [1-40]-formed channels., *Cell. Mol. Neurobiol.* 21 (2001) 255–284.
- [276] M. Ramsden, Z. Henderson, H.A. Pearson, Modulation of Ca²⁺ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status., *Brain Res.* 956 (2002) 254–261.
- [277] R. Bhatia, H. Lin, R. Lal, Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity., *FASEB J.* 14 (2000) 1233–1243.
- [278] H. Lin, R. Bhatia, R. Lal, Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology., *FASEB J.* 15 (2001) 2433–2444. doi:10.1096/fj.01-0377com.
- [279] A. Demuro, E. Mina, R. Kaye, S.C. Milton, I. Parker, C.G. Glabe, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers., *J. Biol. Chem.* 280 (2005) 17294–17300. doi:10.1074/jbc.M500997200.
- [280] P.M. Andersen, Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene., *Curr. Neurol. Neurosci. Rep.* 6 (2006) 37–46.
<http://www.ncbi.nlm.nih.gov/pubmed/16469270>.
- [281] K.P. Kepp, Genotype-Property Patient-Phenotype Relations Suggest that Proteome Exhaustion Can Cause Amyotrophic Lateral Sclerosis, *PLoS One*. 10 (2015) e0118649.
doi:10.1371/journal.pone.0118649.
- [282] T.A. Bayer, S. Schafer, A. Simons, A. Kemmling, T. Kamer, R. Tepest, et al., Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice., *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 14187–14192.
doi:10.1073/pnas.2332818100.
- [283] S. Sinha, J.P. Anderson, R. Barbour, G.S. Basi, R. Caccavello, D. Davis, et al., Purification and cloning of amyloid precursor protein [beta]-secretase from human brain, *Nature*. 402 (1999) 537–540. <http://dx.doi.org/10.1038/990114>.
- [284] B. Angeletti, K.J. Waldron, K.B. Freeman, H. Bawagan, I. Hussain, C.C.J. Miller, et al., BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper., *J. Biol. Chem.* 280 (2005) 17930–17937. doi:10.1074/jbc.M412034200.
- [285] C. Dingwall, A copper-binding site in the cytoplasmic domain of BACE1 identifies a possible link to metal homeostasis and oxidative stress in Alzheimer's disease., *Biochem. Soc. Trans.* 35 (2007) 571–573. doi:10.1042/BST0350571.
- [286] P. Hou, G. Liu, Y. Zhao, Z. Shi, Q. Zheng, G. Bu, et al., Role of copper and the copper-related protein CUTA in mediating APP processing and Abeta generation., *Neurobiol. Aging*. 36 (2015) 1310–1315. doi:10.1016/j.neurobiolaging.2014.12.005.

- [287] L.M. Munter, H. Sieg, T. Bethge, F. Liebsch, F.S. Bierkandt, M. Schleege, et al., Model peptides uncover the role of the beta-secretase transmembrane sequence in metal ion mediated oligomerization., *J. Am. Chem. Soc.* 135 (2013) 19354–19361. doi:10.1021/ja410812r.
- [288] M. Gough, S. Blanthorn-Hazell, E.T. Parkin, The histidine composition of the amyloid-beta domain, but not the E1 copper binding domain, modulates beta-secretase processing of amyloid-beta protein precursor in Alzheimer's disease., *J. Alzheimers. Dis.* 43 (2015) 1163–1168. doi:10.3233/JAD-141650.
- [289] J.-Y. Lee, J.E. Friedman, I. Angel, A. Kozak, J.-Y. Koh, The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice., *Neurobiol. Aging*. 25 (2004) 1315–1321. doi:10.1016/j.neurobiolaging.2004.01.005.
- [290] A. Venti, T. Giordano, P. Eder, A.I. Bush, D.K. Lahiri, N.H. Greig, et al., The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region., *Ann. N. Y. Acad. Sci.* 1035 (2004) 34–48. doi:10.1196/annals.1332.003.
- [291] M. Ho, D.E. Hoke, Y.J. Chua, Q.-X. Li, J.G. Culvenor, C. Masters, et al., Effect of Metal Chelators on gamma-Secretase Indicates That Calcium and Magnesium Ions Facilitate Cleavage of Alzheimer Amyloid Precursor Substrate., *Int. J. Alzheimers. Dis.* 2011 (2010) 950932. doi:10.4061/2011/950932.
- [292] M. Lang, Q. Fan, L. Wang, Y. Zheng, G. Xiao, X. Wang, et al., Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of *Drosophila* ameliorates Abeta42-induced Alzheimer's disease-like symptoms., *Neurobiol. Aging*. 34 (2013) 2604–2612. doi:10.1016/j.neurobiolaging.2013.05.029.
- [293] D.L. Sparks, B.G. Schreurs, Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease., *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 11065–11069. doi:10.1073/pnas.1832769100.
- [294] S.S. Leal, H.M. Botelho, C.M. Gomes, Metal ions as modulators of protein conformation and misfolding in neurodegeneration, *Coord. Chem. Rev.* 256 (2012) 2253–2270. doi:10.1016/j.ccr.2012.04.004.
- [295] W. Wu, P. Lei, Q. Liu, J. Hu, A.P. Gunn, M. Chen, et al., Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents., *J. Biol. Chem.* 283 (2008) 31657–31664. doi:10.1074/jbc.M804722200.
- [296] L. Perrone, E. Mothes, M. Vignes, A. Mockel, C. Figueroa, M.-C. Miquel, et al., Copper transfer from Cu-Abeta to human serum albumin inhibits aggregation, radical production and reduces Abeta toxicity., *Chembiochem*. 11 (2010) 110–118. doi:10.1002/cbic.200900474.
- [297] S.K. Singh, P. Sinha, L. Mishra, S. Srikrishna, Neuroprotective Role of a Novel Copper Chelator against Abeta 42 Induced Neurotoxicity., *Int. J. Alzheimers. Dis.* 2013 (2013) 567128. doi:10.1155/2013/567128.
- [298] J. Ceccom, F. Cosledan, H. Halley, B. Frances, J.M. Lassalle, B. Meunier, Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse model., *PLoS One*. 7 (2012) e43105. doi:10.1371/journal.pone.0043105.
- [299] M. Suarez-Calvet, O. Belbin, M. Pera, N. Badiola, J. Magrane, C. Guardia-Laguarta, et al., Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor

protein differentially alter Abeta production., *J. Neurochem.* 128 (2014) 330–339.
doi:10.1111/jnc.12466.

- [300] N. Brouwers, K. Sleegers, C. Van Broeckhoven, Molecular genetics of Alzheimer's disease: an update., *Ann. Med.* 40 (2008) 562–583. doi:10.1080/07853890802186905.
- [301] S. Kumar-Singh, J. Theuns, B. Van Broeck, D. Pirici, K. Vennekens, Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased A β 42 and decreased A β 40, *Hum. Mutat.* 27 (2006) 686–695.
- [302] D.K. Lahiri, B. Maloney, Beyond the signaling effect role of amyloid-ss42 on the processing of APP, and its clinical implications., *Exp. Neurol.* 225 (2010) 51–54.
doi:10.1016/j.expneurol.2010.04.018.
- [303] M.P. Mattson, ER calcium and Alzheimer's disease: in a state of flux., *Sci. Signal.* 3 (2010) pe10. doi:10.1126/scisignal.3114pe10.
- [304] F.M. Burnet, A possible role of zinc in the pathology of dementia., *Lancet (London, England).* 1 (1981) 186–188.
- [305] P. Faller, C. Hureau, Metal ions in neurodegenerative diseases, *Coord. Chem. Rev.* 256 (2012) 2127–2128. doi:10.1016/j.ccr.2012.04.006.
- [306] L.-H. Zhang, X. Wang, Z.-H. Zheng, H. Ren, M. Stoltenberg, G. Danscher, et al., Altered expression and distribution of zinc transporters in APP/PS1 transgenic mouse brain., *Neurobiol. Aging.* 31 (2010) 74–87. doi:10.1016/j.neurobiolaging.2008.02.018.
- [307] L.-H. Zhang, X. Wang, M. Stoltenberg, G. Danscher, L. Huang, Z.-Y. Wang, Abundant expression of zinc transporters in the amyloid plaques of Alzheimer's disease brain., *Brain Res. Bull.* 77 (2008) 55–60. doi:10.1016/j.brainresbull.2008.03.014.
- [308] P.A. Adlard, J.M. Parncutt, D.I. Finkelstein, A.I. Bush, Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease?, *J. Neurosci.* 30 (2010) 1631–1636. doi:10.1523/JNEUROSCI.5255-09.2010.
- [309] J. Hidalgo, J. Carrasco, A. Quintana, A. Molinero, S. Florit, M. Giralt, et al., Metallothionein I, II and III in Alzheimer Disease and Animal Models of Neuroinflammation, *Exp. Biol. Med.* (2006) 1450–1458.
- [310] V. Wilquet, B. De Strooper, Amyloid-beta precursor protein processing in neurodegeneration., *Curr. Opin. Neurobiol.* 14 (2004) 582–588. doi:10.1016/j.conb.2004.08.001.
- [311] J.S. Miners, N. Barua, P.G. Kehoe, S. Gill, S. Love, Abeta-degrading enzymes: potential for treatment of Alzheimer disease., *J. Neuropathol. Exp. Neurol.* 70 (2011) 944–959.
doi:10.1097/NEN.0b013e3182345e46.
- [312] Y. Liu, C. Studzinski, T. Beckett, M.P. Murphy, R.L. Klein, L.B. Hersh, Circulating neprilysin clears brain amyloid., *Mol. Cell. Neurosci.* 45 (2010) 101–107. doi:10.1016/j.mcn.2010.05.014.
- [313] H. Kanemitsu, T. Tomiyama, H. Mori, Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form., *Neurosci. Lett.* 350 (2003) 113–116.
- [314] J. Hu, A. Igarashi, M. Kamata, H. Nakagawa, Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril

formation; and inhibits cytotoxicity., *J. Biol. Chem.* 276 (2001) 47863–47868.
doi:10.1074/jbc.M104068200.

- [315] K.-J. Yin, J.R. Cirrito, P. Yan, X. Hu, Q. Xiao, X. Pan, et al., Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism., *J. Neurosci.* 26 (2006) 10939–10948. doi:10.1523/JNEUROSCI.2085-06.2006.
- [316] J.R. Backstrom, C.A. Miller, Z.A. Tokes, Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus., *J. Neurochem.* 58 (1992) 983–992.
- [317] J.R. Backstrom, G.P. Lim, M.J. Cullen, Z.A. Tokes, Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40)., *J. Neurosci.* 16 (1996) 7910–7919.
- [318] I. V Kurochkin, S. Goto, Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme., *FEBS Lett.* 345 (1994) 33–37.
- [319] J.R. McDermott, A.M. Gibson, Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme., *Neurochem. Res.* 22 (1997) 49–56.
- [320] E. Gaggelli, H. Kozlowski, D. Valensin, G. Valensin, Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis), *Chem. Rev.* 106 (2006) 1995–2044. doi:10.1021/cr040410w.
- [321] M.J. Berridge, M.D. Bootman, P. Lipp, Calcium-a life and death signal, *Nature.* 395 (1998) 645–648.
- [322] T.A. McKinsey, C.L. Zhang, E.N. Olson, MEF2: a calcium-dependent regulator of cell division, differentiation and death, *Trends Biochem. Sci.* 27 (2002) 40–47.
- [323] S. Orrenius, B. Zhivotovsky, P. Nicotera, Regulation of cell death: the calcium–apoptosis link, *Nat. Rev. Mol. Cell Biol.* 4 (2003) 552–565.
- [324] P.J. Fraker, W.G. Telford, A Reappraisal of the Role of Zinc in Life and Death Decisions of Cells, *Exp. Biol. Med.* . 215 (1997) 229–236. doi:10.3181/00379727-215-44132.
- [325] A.Q. Truong-Tran, J. Carter, R.E. Ruffin, P.D. Zalewski, The role of zinc in caspase activation and apoptotic cell death, *Biomaterials.* 14 (2001) 315–330.
- [326] F. Chimienti, M. Seve, S. Richard, J. Mathieu, A. Favier, Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases, and cleavage of Sp family transcription factors, *Biochem. Pharmacol.* 62 (2001) 51–62.
- [327] K.-D. Kroncke, Cellular stress and intracellular zinc dyshomeostasis., *Arch. Biochem. Biophys.* 463 (2007) 183–187. doi:10.1016/j.abb.2007.03.008.
- [328] B.K.Y. Bitanihirwe, M.G. Cunningham, Zinc: the brain's dark horse., *Synapse.* 63 (2009) 1029–1049. doi:10.1002/syn.20683.
- [329] D. Oberleas, Mechanism of zinc homeostasis., *J. Inorg. Biochem.* 62 (1996) 231–241.
- [330] M.A. Aras, E. Aizenman, Redox regulation of intracellular zinc: molecular signaling in the life and death of neurons, *Antioxid. Redox Signal.* 15 (2011) 2249–2263.

- [331] D. Guo, Y. Du, Q. Wu, W. Jiang, H. Bi, Disrupted calcium homeostasis is involved in elevated zinc ion-induced photoreceptor cell death., *Arch. Biochem. Biophys.* 560 (2014) 44–51. doi:10.1016/j.abb.2014.07.014.
- [332] S.-H. Baek, M.-Y. Kim, J.-S. Mo, E.-J. Ann, K.S. Lee, J.-H. Park, et al., Zinc-induced downregulation of Notch signaling is associated with cytoplasmic retention of Notch1-IC and RBP-Jk via PI3k-Akt signaling pathway., *Cancer Lett.* 255 (2007) 117–126. doi:10.1016/j.canlet.2007.04.002.
- [333] J.S. Becker, M. V Zoriy, C. Pickhardt, N. Palomero-Gallagher, K. Zilles, Imaging of copper, zinc, and other elements in thin section of human brain samples (hippocampus) by laser ablation inductively coupled plasma mass spectrometry., *Anal. Chem.* 77 (2005) 3208–3216. doi:10.1021/ac040184q.
- [334] J. Dobrowolska, M. Dehnhardt, A. Matusch, M. Zoriy, N. Palomero-Gallagher, P. Koscielniak, et al., Quantitative imaging of zinc, copper and lead in three distinct regions of the human brain by laser ablation inductively coupled plasma mass spectrometry., *Talanta.* 74 (2008) 717–723. doi:10.1016/j.talanta.2007.06.051.
- [335] Z.-Y. Wang, J.-Y. Li, G. Danscher, A. Dahlstrom, Localization of zinc-enriched neurons in the mouse peripheral sympathetic system., *Brain Res.* 928 (2002) 165–174.
- [336] J. Wojtkiewicz, M. Rowniak, R. Crayton, M. Majewski, S. Gonkowski, Chemical coding of zinc-enriched neurons in the intramural ganglia of the porcine jejunum., *Cell Tissue Res.* 350 (2012) 215–223. doi:10.1007/s00441-012-1486-5.
- [337] S.W. Suh, K.B. Jensen, M.S. Jensen, D.S. Silva, P.J. Kessler, G. Danscher, et al., Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains, *Brain Res.* 852 (2000) 274–278. doi:http://dx.doi.org/10.1016/S0006-8993(99)02096-X.
- [338] G. Danscher, K.B. Jensen, C.J. Frederickson, K. Kemp, A. Andreasen, S. Juhl, et al., Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: A proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material, *J. Neurosci. Methods.* 76 (1997) 53–59. doi:http://dx.doi.org/10.1016/S0165-0270(97)00079-4.
- [339] R. a Saccon, R.K. a Bunton-Stasyshyn, E.M.C. Fisher, P. Fratta, Is SOD1 loss of function involved in amyotrophic lateral sclerosis?, *Brain.* 136 (2013) 2342–58. doi:10.1093/brain/awt097.
- [340] J. Valentine, P. Doucette, S.Z. Potter, Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis, *Annu. Rev. Biochem.* 74 (2005) 563–593. doi:10.1146/annurev.biochem.72.121801.161647.
- [341] D.R. Rosen, T. Siddique, D. Patterson, D.A. Figlewicz, P. Sapp, A. Hentati, et al., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis., *Nature.* 362 (1993) 59–62. doi:10.1038/362059a0.
- [342] K.-H. Baek, A. Zaslavsky, R.C. Lynch, C. Britt, Y. Okada, R.J. Siarey, et al., Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1., *Nature.* 459 (2009) 1126–1130. doi:10.1038/nature08062.
- [343] V. Vassiliev, Z.L. Harris, P. Zatta, Ceruloplasmin in neurodegenerative diseases, *Brain Res.*

Rev. 49 (2005) 633–640. doi:10.1016/j.brainresrev.2005.03.003.

- [344] E. Tiffany-Castiglioni, S. Hong, Y. Qian, Copper handling by astrocytes: Insights into neurodegenerative diseases, *Int. J. Dev. Neurosci.* 29 (2011) 811–818. doi:10.1016/j.ijdevneu.2011.09.004.
- [345] A. Van Ho, D.M. Ward, J. Kaplan, Transition metal transport in yeast., *Annu. Rev. Microbiol.* 56 (2002) 237–261. doi:10.1146/annurev.micro.56.012302.160847.
- [346] M.A. Greenough, I. Volitakis, Q.-X. Li, K. Laughton, G. Evin, M. Ho, et al., Presenilins promote the cellular uptake of copper and zinc and maintain copper chaperone of SOD1-dependent copper/zinc superoxide dismutase activity., *J. Biol. Chem.* 286 (2011) 9776–9786. doi:10.1074/jbc.M110.163964.
- [347] C. Supnet, I. Bezprozvanny, Presenilins function in ER calcium leak and Alzheimer's disease pathogenesis, *Cell Calcium*. 50 (2011) 303–309. doi:10.1016/j.ceca.2011.05.013.
- [348] Q. Guo, K. Furukawa, B.L. Sopher, D.G. Pham, J. Xie, N. Robinson, et al., Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide., *Neuroreport*. 8 (1996) 379–383.
- [349] S. Scheuermann, B. Hambsch, L. Hesse, J. Stumm, C. Schmidt, D. Beher, et al., Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease., *J. Biol. Chem.* 276 (2001) 33923–33929. doi:10.1074/jbc.M105410200.
- [350] Y. Noda, M. Asada, M. Kubota, M. Maesako, K. Watanabe, M. Uemura, et al., Copper enhances APP dimerization and promotes A β production., *Neurosci. Lett.* 547 (2013) 10–15. doi:10.1016/j.neulet.2013.04.057.
- [351] C.-Y. Wang, T. Wang, W. Zheng, B.-L. Zhao, G. Danscher, Y.-H. Chen, et al., Zinc Overload Enhances APP Cleavage and A β Deposition in the Alzheimer Mouse Brain, *PLoS One*. 5 (2010) e15349. <http://dx.doi.org/10.1371/journal.pone.0015349>.
- [352] C. Haass, C.A. Lemere, A. Capell, M. Citron, P. Seubert, D. Schenk, et al., The Swedish mutation causes early-onset Alzheimer's disease by [beta]-secretase cleavage within the secretory pathway, *Nat Med.* 1 (1995) 1291–1296. <http://dx.doi.org/10.1038/nm1295-1291>.
- [353] C. Nilsberth, A. Westlind-Danielsson, C.B. Eckman, M.M. Condron, K. Axelman, C. Forsell, et al., The “Arctic” APP mutation (E693G) causes Alzheimer's disease by enhanced A β protofibril formation., *Nat. Neurosci.* 4 (2001) 887–893. doi:10.1038/nn0901-887.
- [354] A. Baumketner, M.G. Krone, J.-E. Shea, Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15-28 fragment of the Alzheimer amyloid-beta protein., *Proc. Natl. Acad. Sci. U. S. A.* 105 (2008) 6027–6032. doi:10.1073/pnas.0708193105.
- [355] J.A. Maloney, T. Bainbridge, A. Gustafson, S. Zhang, R. Kyauk, P. Steiner, et al., Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein., *J. Biol. Chem.* 289 (2014) 30990–31000. doi:10.1074/jbc.M114.589069.
- [356] S.C. Drew, K.J. Barnham, The heterogeneous nature of Cu²⁺ interactions with Alzheimer's amyloid-beta peptide, *Acc Chem Res.* 44 (2011) 1146–1155. doi:10.1021/ar200014u.
- [357] J.H. Viles, Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc

and iron in Alzheimer's, Parkinson's and prion diseases, *Coord. Chem. Rev.* 256 (2012) 2271–2284. doi:10.1016/j.ccr.2012.05.003.

- [358] W.T. Chen, C.J. Hong, Y.T. Lin, W.H. Chang, H.T. Huang, J.Y. Liao, et al., Amyloid-beta (A β) D7H mutation increases oligomeric A β 42 and alters properties of A β -zinc/copper assemblies, *PLoS One*. 7 (2012) e35807. doi:10.1371/journal.pone.0035807.
- [359] A. Clements, D. Allsop, D.M. Walsh, C.H. Williams, Aggregation and Metal-Binding Properties of Mutant Forms of the Amyloid A β Peptide of Alzheimer's Disease, *J. Neurochem.* 66 (1996) 740–747. doi:10.1046/j.1471-4159.1996.66020740.x.
- [360] B. De Strooper, T. Iwatsubo, M.S. Wolfe, Presenilins and γ -secretase: structure, function, and role in Alzheimer Disease., *Cold Spring Harb. Perspect. Med.* 2 (2012) a006304. doi:10.1101/cshperspect.a006304.
- [361] H. Tu, O. Nelson, A. Bezprozvanny, Z. Wang, S.-F. Lee, Y.-H. Hao, et al., Presenilins form ER Ca²⁺ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations., *Cell*. 126 (2006) 981–993. doi:10.1016/j.cell.2006.06.059.
- [362] L. Sun, L. Zhao, G. Yang, C. Yan, R. Zhou, X. Zhou, et al., Structural basis of human γ -secretase assembly., *Proc. Natl. Acad. Sci. U. S. A.* 112 (2015) 6003–6008. doi:10.1073/pnas.1506242112.
- [363] H. Laudon, E.M. Hansson, K. Melén, A. Bergman, M.R. Farmery, B. Winblad, et al., A nine-transmembrane domain topology for presenilin 1., *J. Biol. Chem.* 280 (2005) 35352–60. doi:10.1074/jbc.M507217200.
- [364] M.S. Wolfe, Toward the structure of presenilin/ γ -secretase and presenilin homologs, *Biochim. Biophys. Acta - Biomembr.* 1828 (2013) 2886–2897. doi:10.1016/j.bbamem.2013.04.015.
- [365] H.K. Das, K. Tchedre, B. Mueller, Repression of transcription of presenilin-1 inhibits gamma-secretase independent ER Ca²⁺(+) leak that is impaired by FAD mutations., *J. Neurochem.* 122 (2012) 487–500. doi:10.1111/j.1471-4159.2012.07794.x.
- [366] D. Shilling, D.-O.D. Mak, D.E. Kang, J.K. Foskett, Lack of evidence for presenilins as endoplasmic reticulum Ca²⁺ leak channels., *J. Biol. Chem.* 287 (2012) 10933–10944. doi:10.1074/jbc.M111.300491.
- [367] M. McBrayer, R.A. Nixon, Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime., *Biochem. Soc. Trans.* 41 (2013) 1495–1502. doi:10.1042/BST20130201.
- [368] K. Honarnejad, J. Herms, Presenilins: role in calcium homeostasis., *Int. J. Biochem. Cell Biol.* 44 (2012) 1983–1986. doi:10.1016/j.biocel.2012.07.019.
- [369] Q. Guo, N. Robinson, M.P. Mattson, Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and stabilization of calcium homeostasis., *J. Biol. Chem.* 273 (1998) 12341–12351.
- [370] J. Perry, D. Shin, E. Getzoff, J. Tainer, The structural biochemistry of the superoxide dismutases, *Biochim. Biophys. Acta.* 1804 (2010) 245–262. doi:10.1016/j.bbapap.2009.11.004.
- [371] A.E. Renton, A. Chiò, B.J. Traynor, State of play in amyotrophic lateral sclerosis genetics., *Nat. Neurosci.* 17 (2014) 17–23. doi:10.1038/nn.3584.
- [372] C.-C. Tan, J.-T. Yu, M.-S. Tan, T. Jiang, X.-C. Zhu, L. Tan, Autophagy in aging and

- neurodegenerative diseases: implications for pathogenesis and therapy., *Neurobiol. Aging*. 35 (2014) 941–957. doi:10.1016/j.neurobiolaging.2013.11.019.
- [373] R.A. Nixon, D.-S. Yang, Autophagy failure in Alzheimer's disease--locating the primary defect., *Neurobiol. Dis.* 43 (2011) 38–45. doi:10.1016/j.nbd.2011.01.021.
- [374] Y.-T. Tung, B.-J. Wang, M.-K. Hu, W.-M. Hsu, H. Lee, W.-P. Huang, et al., Autophagy: a double-edged sword in Alzheimer's disease., *J. Biosci.* 37 (2012) 157–165.
- [375] X.-C. Zhu, J.-T. Yu, T. Jiang, L. Tan, Autophagy modulation for Alzheimer's disease therapy., *Mol. Neurobiol.* 48 (2013) 702–714. doi:10.1007/s12035-013-8457-z.
- [376] J.-H. Lee, W.H. Yu, A. Kumar, S. Lee, P.S. Mohan, C.M. Peterhoff, et al., Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations., *Cell*. 141 (2010) 1146–1158. doi:10.1016/j.cell.2010.05.008.
- [377] A.M. Cataldo, C.M. Peterhoff, S.D. Schmidt, N.B. Terio, K. Duff, M. Beard, et al., Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology., *J. Neuropathol. Exp. Neurol.* 63 (2004) 821–830.
- [378] C. Gonzalez, T. Martin, J. Cacho, M.T. Brenas, T. Arroyo, B. Garcia-Berrocal, et al., Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers., *Eur. J. Clin. Invest.* 29 (1999) 637–642.
- [379] J.Y. Wu, S.K. Reaves, Y.R. Wang, Y. Wu, P.P. Lei, K.Y. Lei, Zinc deficiency decreases plasma level and hepatic mRNA abundance of apolipoprotein A-I in rats and hamsters., *Am. J. Physiol.* 275 (1998) C1516–25.
- [380] K.Y. Lei, C.A. Hassel, D.K. Allen, Alterations in plasma lipid, lipoprotein and apolipoprotein concentrations in copper-deficient rats, *J Nutr.* 113 (1983) 2178–2183.
- [381] S.C. Croswell, K.Y. Lei, Effect of Copper Deficiency on the Apolipoprotein E-Rich High Density Lipoproteins in Rats, *J. Nutr.* 115 (1985) 473–482.
- [382] F.M. Harris, W.J. Brecht, Q. Xu, R.W. Mahley, Y. Huang, Increased tau Phosphorylation in Apolipoprotein E4 Transgenic Mice Is Associated with Activation of Extracellular Signal-regulated Kinase: MODULATION BY ZINC, *J. Biol. Chem.* . 279 (2004) 44795–44801. doi:10.1074/jbc.M408127200.
- [383] I.P. Trougakos, G. Pawelec, C. Tzavelas, T. Ntouriopi, E.S. Gonos, Clusterin/Apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells, *Biogerontology*. 7 (2006) 375–382. doi:10.1007/s10522-006-9052-8.
- [384] S. Materia, M.A. Cater, L.W.J. Klomp, J.F.B. Mercer, S. La Fontaine, Clusterin (Apolipoprotein J), a Molecular Chaperone That Facilitates Degradation of the Copper-ATPases ATP7A and ATP7B, *J. Biol. Chem.* . 286 (2011) 10073–10083. <http://www.jbc.org/content/286/12/10073.abstract>.
- [385] D.J. Waggoner, T.B. Bartnikas, J.D. Gitlin, The role of copper in neurodegenerative disease., *Neurobiol. Dis.* 6 (1999) 221–230. doi:10.1006/nbdi.1999.0250.
- [386] T. Litwin, G. Gromadzka, A. Czlonkowska, Apolipoprotein E gene (APOE) genotype in Wilson's disease: impact on clinical presentation., *Parkinsonism Relat. Disord.* 18 (2012) 367–369. doi:10.1016/j.parkreldis.2011.12.005.

- [387] M. Mullan, F. Crawford, K. Axelman, H. Houlden, L. Lilius, B. Winblad, et al., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid., *Nat. Genet.* 1 (1992) 345–347. doi:10.1038/ng0892-345.
- [388] M. Citron, T. Oltersdorf, C. Haass, L. McConlogue, A.Y. Hung, P. Seubert, et al., Mutation of the [beta]-amyloid precursor protein in familial Alzheimer's disease increases [beta]-protein production, *Nature*. 360 (1992) 672–674. <http://dx.doi.org/10.1038/360672a0>.
- [389] X.D. Cai, T.E. Golde, S.G. Younkin, Release of excess amyloid beta protein from a mutant amyloid beta protein precursor, *Science* (80-.). 259 (1993) 514–516. <http://science.sciencemag.org/content/259/5094/514.abstract>.
- [390] K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, et al., Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice., *Science*. 274 (1996) 99–102. doi:10.1126/science.274.5284.99.
- [391] G.A. Elder, M.A. Gama Sosa, R. De Gasperi, Transgenic mouse models of Alzheimer's disease., *Mt. Sinai J. Med.* 77 (2010) 69–81. doi:10.1002/msj.20159.
- [392] J.-Y. Lee, T.B. Cole, R.D. Palmiter, S.W. Suh, J.-Y. Koh, Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice, *Proc. Natl. Acad. Sci. U. S. A.* 99 (2002) 7705–7710. doi:10.1073/pnas.092034699.
- [393] X. Lv, W. Li, Y. Luo, D. Wang, C. Zhu, Z.-X. Huang, et al., Exploring the differences between mouse mA[small beta]1-42 and human hA[small beta]1-42 for Alzheimer{'}'s disease related properties and neuronal cytotoxicity, *Chem. Commun.* 49 (2013) 5865–5867. doi:10.1039/C3CC40779A.
- [394] D. Kim, J.K. Bang, S.H. Kim, Multi-Frequency, Multi-Technique Pulsed EPR Investigation of the Copper Binding Site of Murine Amyloid β Peptide, *Angew. Chemie Int. Ed.* 54 (2015) 1561–1564. doi:10.1002/anie.201410389.
- [395] D. Boyd-Kimball, R. Sultana, H. Mohmmad-Abdul, D.A. Butterfield, Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): Implications for proposed mechanisms of toxicity., *J. Alzheimers. Dis.* 6 (2004) 515–525.
- [396] J. Kuret, E.E. Congdon, G. Li, H. Yin, X. Yu, Q. Zhong, Evaluating triggers and enhancers of tau fibrillization, *Microsc. Res. Tech.* 67 (2005) 141–155. doi:10.1002/jemt.20187.
- [397] M. von Bergen, S. Barghorn, J. Biernat, E.-M. Mandelkow, E. Mandelkow, Tau aggregation is driven by a transition from random coil to beta sheet structure, *Biochim. Biophys. Acta.* 1739 (2005) 158–166. doi:10.1016/j.bbadis.2004.09.010.
- [398] Y. Huang, Z. Wu, Y. Cao, M. Lang, B. Lu, B. Zhou, Zinc binding directly regulates tau toxicity independent of tau hyperphosphorylation, *Cell Rep.* 8 (2014) 831–842. doi:10.1016/j.celrep.2014.06.047.
- [399] I. Kim, E.J. Park, J. Seo, S.J. Ko, J. Lee, C.H. Kim, Zinc stimulates tau S214 phosphorylation by the activation of Raf/mitogen-activated protein kinase-kinase/extracellular signal-regulated kinase pathway, *Neuroreport*. 22 (2011) 839–844. doi:10.1097/wnr.0b013e32834c0a2d.
- [400] Z.-Y. Mo, Y.-Z. Zhu, H.-L. Zhu, J.-B. Fan, J. Chen, Y. Liang, Low micromolar zinc accelerates the fibrillization of human tau via bridging of Cys-291 and Cys-322, *J. Biol. Chem.* 284 (2009) 34648–34657. doi:10.1074/jbc.m109.058883.

- [401] V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, et al., Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, *Lancet Neurol.* 12 (2013) 357–367. doi:[http://dx.doi.org/10.1016/S1474-4422\(13\)70044-9](http://dx.doi.org/10.1016/S1474-4422(13)70044-9).
- [402] K.A. Johnson, S. Minoshima, N.I. Bohnen, K.J. Donohoe, N.L. Foster, P. Herscovitch, et al., Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association, *J. Nucl. Med.* 54 (2013) 476–490.
- [403] R.J. Bateman, C. Xiong, T.L.S. Benzinger, A.M. Fagan, A. Goate, N.C. Fox, et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease., *N. Engl. J. Med.* 367 (2012) 795–804. doi:[10.1056/NEJMoal202753](https://doi.org/10.1056/NEJMoal202753).
- [404] S. Palmqvist, H. Zetterberg, N. Mattsson, P. Johansson, L. Minthon, K. Blennow, et al., Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease, *Neurology.* 85 (2015) 1240–1249.
- [405] C.R. Jack Jr, D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, P.S. Aisen, et al., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, *Lancet Neurol.* 12 (2013) 207–216. doi:[http://dx.doi.org/10.1016/S1474-4422\(12\)70291-0](http://dx.doi.org/10.1016/S1474-4422(12)70291-0).
- [406] R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, et al., Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment., *Ann. Neurol.* 30 (1991) 572–580. doi:[10.1002/ana.410300410](https://doi.org/10.1002/ana.410300410).
- [407] P.D. Coleman, P.J. Yao, Synaptic slaughter in Alzheimer's disease., *Neurobiol. Aging.* 24 (2003) 1023–1027.
- [408] A.V.J. Terry, J.J. Buccafusco, The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development., *J. Pharmacol. Exp. Ther.* 306 (2003) 821–827. doi:[10.1124/jpet.102.041616](https://doi.org/10.1124/jpet.102.041616).
- [409] S.E. Hoey, R.J. Williams, M.S. Perkinson, Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production., *J. Neurosci.* 29 (2009) 4442–4460. doi:[10.1523/JNEUROSCI.6017-08.2009](https://doi.org/10.1523/JNEUROSCI.6017-08.2009).
- [410] H. Furukawa, S.K. Singh, R. Mancusso, E. Gouaux, Subunit arrangement and function in NMDA receptors., *Nature.* 438 (2005) 185–192. doi:[10.1038/nature04089](https://doi.org/10.1038/nature04089).
- [411] F. Li, J.Z. Tsien, Memory and the NMDA receptors., *N. Engl. J. Med.* 361 (2009) 302–303. doi:[10.1056/NEJMcibr0902052](https://doi.org/10.1056/NEJMcibr0902052).
- [412] P.N. Lacor, M.C. Buniel, L. Chang, S.J. Fernandez, Y. Gong, K.L. Viola, et al., Synaptic targeting by Alzheimer's-related amyloid beta oligomers., *J. Neurosci.* 24 (2004) 10191–10200. doi:[10.1523/JNEUROSCI.3432-04.2004](https://doi.org/10.1523/JNEUROSCI.3432-04.2004).
- [413] B. Calabrese, G.M. Shaked, I. V Tabarean, J. Braga, E.H. Koo, S. Halpain, Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein., *Mol. Cell. Neurosci.* 35 (2007) 183–193. doi:[10.1016/j.mcn.2007.02.006](https://doi.org/10.1016/j.mcn.2007.02.006).
- [414] K.L. Viola, P.T. Velasco, W.L. Klein, Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs)., *J. Nutr. Health Aging.* 12 (2008) 51S–7S.

- [415] M. Ramsden, L.D. Plant, N.J. Webster, P.F. Vaughan, Z. Henderson, H.A. Pearson, Differential effects of unaggregated and aggregated amyloid beta protein (1-40) on K(+) channel currents in primary cultures of rat cerebellar granule and cortical neurones., *J. Neurochem.* 79 (2001) 699–712.
- [416] P.I. Moreira, S.L. Siedlak, G. Aliev, X. Zhu, A.D. Cash, M.A. Smith, et al., Oxidative stress mechanisms and potential therapeutics in Alzheimer disease, *J. Neural Transm. J. Neural Transm, J Neural Tr, J Neural Transm, J. Neural Transm. Gen. Sect. J Neural Transm Gen Sect, J. Neural Transm. Basic Neurosci. J. Neural Transm. (vienna, Austria.* 112 (2005) 921–932. doi:10.1007/s00702-004-0242-8.
- [417] J.N. Keller, Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease., *J. Biomed. Biotechnol.* 2006 (2006) 12129. doi:10.1155/JBB/2006/12129.
- [418] A. Kitamura, N. Inada, H. Kubota, G. Matsumoto, M. Kinjo, R.I. Morimoto, et al., Dysregulation of the proteasome increases the toxicity of ALS-linked mutant SOD1., *Genes Cells.* 19 (2014) 209–24. doi:10.1111/gtc.12125.
- [419] K.P. Kepp, P. Dasmeh, A model of proteostatic energy cost and its use in analysis of proteome trends and sequence evolution., *PLoS One.* 9 (2014) e90504. doi:10.1371/journal.pone.0090504.
- [420] A. Eckert, S. Hauptmann, I. Scherping, V. Rhein, F. Muller-Spahn, J. Gotz, et al., Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice., *Neurodegener. Dis.* 5 (2008) 157–159. doi:10.1159/000113689.
- [421] R. Lal, H. Lin, A.P. Quist, Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm., *Biochim. Biophys. Acta.* 1768 (2007) 1966–1975. doi:10.1016/j.bbamem.2007.04.021.
- [422] O.I. Okereke, W. Xia, D.J. Selkoe, F. Grodstein, Ten-year change in plasma amyloid β levels and late-life cognitive decline, *Arch. Neurol. Arch. Neurol, Arch Neurol, Arch Neurol Chicago, Arch Neurol-Chicago, Chicago.* 66 (2009) 1247–1253. doi:10.1001/archneurol.2009.207.
- [423] R. Peters, The prevention of dementia, *Int. J. Geriatr. Psychiatry, Int. J. Geriatr. Psychiatr, Int J Ger P, Int J Geriatr Psych, Int J Geriatr Psychiat, Int J Geriatr Psychiatry.* 24 (2009) 452–458. doi:10.1002/gps.2153.